

**Ref. No.:** F.02(42)/RMSCL/PROCUREMENT/DRUG/NIT-1/2013/281    dated  
26.02.2013

**RAJASTHAN MEDICAL SERVICES CORPORATION LTD.**  
**(A Govt. of Rajasthan Undertaking)**  
**Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India**  
**Tel No: 0141-2228066, 2228064, E-mail: rmisc@nic.in**

E-BID for the SUPPLY CUM RATE CONTRACT, and EMPANELMENT FOR  
SUPPLY of Drugs and Medicines FOR THE YEAR 2013-14  
RAJASTHAN MEDICAL SERVICES CORPORATION LTD.  
RAJASTHAN



!! सर्वे सन्तु निरामया:!!

LAST DATE OF SUBMISSION OF ONLINE BIDS 09.04.2013

-  
**Ministry of Health & Family Welfare**  
**Government of Rajasthan**  
RMSCL  
**“Mukhyamantri Nishulk Dava Yojana”**  
**‘D’ Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India**  
**Tel No: 0141-5110736, 2228064, E-mail: rmisc@nic.in**

F.02(42)/RMSCL/Procurement/Drug/NIT-1/2013/281

Date: 26.02.2013

## **Notice Inviting E-Bids**

E-bids are invited upto 1.00 PM of 09.04.2013 for **supply cum rate contract**, and **Empanelment** for supply for drug and medicines for the year 2013-14. Details may be seen in the Bidding Documents at our office or at the website of State Public procurement Portal <http://sppp.raj.nic.in>, [www.dipronline.org](http://www.dipronline.org), <http://eproc.rajasthan.gov.in>, [www.rmisc.nic.in](http://www.rmisc.nic.in) and may be downloaded from there. Tender fee, RISL processing fees and EMD, are to be deposited in the office of RMSCL or through prescribed challan or through D.D. / bankers cheque in favour of M.D. RMSCL (tender fees and EMD), MD, RISL ( tender procession fees) before due time and date of bid submission . **Those who wish to apply for Empanelment as supplier for drugs and medicines are required to deposit separately an Empanelment Fee of Rs 5000 (Five Thousand rupees only) in the form of DD in favour of MD, RMSCL before due time and date of bid submission.**

**Note:-** If any amendment is carried out in the tender specifications and terms & conditions following pre-bid meeting, the same will be uploaded on the *Departmental website* [www.rmisc.nic.in](http://www.rmisc.nic.in), [sppp.raj.nic.in](http://sppp.raj.nic.in) and <https://eproc.rajasthan.gov.in> and will not be published in news papers. In case any inconvenience is felt, please contact on telephone number i.e. 0141-2228064

**Executive Director (Procurement)**  
**RMSCL**

-

**E-BID FOR THE SUPPLY CUM RATE CONTRACT, AND EMPANELMENT FOR  
SUPPLY OF DRUGS AND MEDICINES FOR THE YEAR 2013-14  
RAJASTHAN MEDICAL SERVICES CORPORATION LTD.  
RAJASTHAN**

<b>BID REFERENCE</b>	<b>:</b>	<b>F.02(42)/RMSCL/PROCUREMENT/DRUG NIT-1 /2013/281     dated. 26.02.2013</b>
<b>Pre- bid conference</b>	<b>:</b>	<b>11.3.2013at 11.00 A.M. (RMSC meeting Hall )</b>
<b>Date and time for downloading bid document</b>	<b>:</b>	<b>04.03.2013 from 1.00 PM</b>
<b>Last date and time for Downloading bid document</b>	<b>:</b>	<b>08.04.2013 at 6.00 PM</b>
<b>Last date and time of submission of online bids</b>	<b>:</b>	<b>09.04.2013 at 1.00 PM</b>
<b>Date and time of opening of Online technical bids</b>	<b>:</b>	<b>09.04.2013 at 2.30 PM</b>
<b>COST OF THE BID DOCUMENT</b>	<b>:</b>	<b>Rs. 2000/-</b>
<b>FOR SSI UNIT OF RAJASTHAN</b>	<b>:</b>	<b>Rs. 1000/-</b>
<b>RISL Processing Fees</b>	<b>:</b>	<b>Rs. 1000/-</b>
<b>Empanelment Fee (If applying for Empanelment also)</b>	<b>:</b>	<b>Rs. 5000/-</b>

-

E-BID FOR THE SUPPLY CUM RATE CONTRACT, AND EMPANELMENT FOR  
SUPPLY OF DRUGS AND MEDICINES FOR THE YEAR 2013-14  
RAJASTHAN MEDICAL SERVICES CORPORATION LTD.  
RAJASTHAN

Rajasthan Medical Services Corporation Ltd., (hereinafter referred as **Bids Inviting Authority** unless the context otherwise requires) invites E-BIDS FOR THE SUPPLY CUM RATE CONTRACT AND EMPANELMENT FOR SUPPLY OF DRUGS AND MEDICINES.

1. **LAST DATE FOR RECEIPT OF BIDS, BID FEES, EMD, RISL PROCESSING FEES AND EMPANELMENT FEES**

- (a) E-Bids [in two separate bid (Technical bid & Price Bid)] will be received till 09.04.2013 at 1.00 PM by the Rajasthan Medical Services Corporation Ltd, for the supply cum rate contract and empanelment for supply of drugs & medicines.
- (b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity for another period of 30 days. The Bidder may refuse extension of bid validity without forfeiting the Earnest Money deposit.
- (c) The e-Bids will be received on web-portal of e-procurement of GoR. Every Bidder will be required to pay the Bid form fee Rs. 2000.00 (Rs. 1000.00 for SSI Units of Rajasthan) for downloaded from the website, EMD as applicable in Bid condition no. 8 and processing fee of Rs.1000.00 of R.I.S.L. through three separate prescribed challans (*format enclosed in Annexure- I*) in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country upto 08.04.2013 or through D.D. / bankers cheque in favour of M.D. RMSCL (tender fees and EMD), MD, RISL ( tender procession fees) physically in the office of RMSC by 1.00 PM on 09.04.2013. The

bidders shall submit/upload scanned copy of all the challans in Technical Bid. Bids will be opened only after ensuring receipt of Bid fees along with processing fees and EMD. In the absence of Bid fees and processing fees and EMD the Bids will be rejected and will not be opened.

- (d) **Those who wish to apply for Empanelment as supplier for drugs and medicines** are required to deposit separately an Empanelment Fee of Rs 5000 (Five Thousand rupees only) in the form of DD in favour of MD, RMSC before due time and date of bid submission. Please see clause 20 and annexure-XI in this regard.

## 2. **ELIGIBILITY CRITERIA**

- (a) Bidder shall be a manufacturer having valid own manufacturing license or direct importer holding valid import license. Distributors/ Suppliers / Agents/Loan licensee are not eligible to participate in the Bids.
- (b) Average Annual turnover (*for drugs and medicines including Surgical and sutures Business*) in the last three financial years (2009-10 and 2010-11, 2011-12) shall not be less than **Rs. 20 Crores**. For SSI units of Rajasthan, the average annual turnover in the last three financial years ( 2009-10, 2010-11 and 2011-12) should not be less than **Rs. 2 Crores**. **For drug items falling in the category of “eye preparations” and for drug code no. 243, 564& 594 the average annual turnover of last three years should not be less than Rs. 2 Cr.**
- (c) Bidder should have at least 3 years Market Standing as a manufacturer / importer for the product.
- (d) Bidder should have permission to manufacture the item /drug quoted as per specification given in the Bid, from the competent authority. Product permission of *brands* shall be accepted in the Bid submitted, but the Bidder has to submit the product permission in generic names at the time of signing of the agreement/*before supply*.

- (e) Bid should not be submitted for the product/products for which the concern/company has been blacklisted/banned/debarred either by Bid inviting Authority or Govt. of Rajasthan or by any other State/Central Govt. and its Drugs procurement agencies.
- (f) The concern/company/firm which stands blacklisted/banned/debarred either by Bid Inviting Authority or Govt. of Rajasthan or by any other State/Central Government or its Drugs procurement agencies on the date of bid submission shall not be eligible to participate in the Bid. If a company/firm and any product were blacklisted for a specified period, then the same will become eligible after the blacklisting period is over. In case the period of blacklisting/banning is not specified, the firm shall be eligible to participate after two years of the date of issue of order of banning/blacklisted/debarred.
- (g) If any product/products of a company/firm have been declared as not of standard quality, as per Drugs & Cosmetics Act during last 2 years anywhere, such concern/company/firm shall not be eligible to participate in Bid for such product/products. If any company/firm is found to have any such product quoted in the Bid, the product shall be blacklisted for 2 years and a penalty equivalent to EMD shall also be levied. In such situation, the bid will be considered further only if the amount of penalty is deposited before the completion of technical evaluation.
- (h) The concern/firm/company whose product has been declared as of spurious or adulterated quality and any criminal case is filed and pending in any court shall not be eligible to participate for that particular product, in the Bid. Similarly convicted firm/company shall also not be eligible to participate in the Bid.

### 3. **PURCHASE PREFERENCE**

- i. Purchase preference admissible to the PSUs of the state of Rajasthan and to the SSI of the state of Rajasthan, together shall not exceed 25% (10% for PSUs and 15% of SSI units). However these units will be required to participate in Bidding process and match L-1 price.

ii. **Comparison of rates of firms outside and those in Rajasthan:-**

While tabulating the Bids of those firms which are not entitled to price preference, the element of Rajasthan VAT shall be excluded from the rates quoted by the firms of Rajasthan and the element of CST shall be included in the rates quoted by the firms of outside Rajasthan. In such case if the price of any commodity being offered for sale by firms in Rajasthan is the same or lower (excluding Rajasthan VAT) than the price of firm outside Rajasthan (including element of CST), the commodity shall be purchased from the firm in Rajasthan.

- iii. VAT on drugs and medicines are exempted in Rajasthan. RMSCL will issue necessary exempted certificate.
- iv. RMSC will also issue “C-certificate” in case of interstate supply. Therefore concessional CST should be charged

4. **GENERAL CONDITIONS**

- i. At any time prior to the date of submission of Bid, Bid Inviting Authority may, for any reason, whether on his own initiatives or in response to a clarification requested by a prospective Bidder, modify the condition in Bid documents by amendment. In order to provide reasonable time to take the amendment into account in preparing their bid, Bid Inviting Authority may at his discretion, extended the date and time for submission of Bids.
- ii. Interested eligible Bidders may obtain further information in this regard from the office of the Bid Inviting Authority.
- iii. ***In case any document submitted by the bidder or his authorized representative is found to be forged, false or fabricated, the bid will be rejected and EMD/SD will be forfeited. Bidder/his representative may also be blacklisted/banned/debarred. Report with police station may also be filed against such bidder/his representative.***

## 5. TECHNICAL BID

The Bidder should furnish the following in technical bid :-

- (a) Tenderers are allowed the option to quote for anyone item or more items as mentioned in tender (list of medicines proposed to be purchased at Annexure-VIII). The amount of EMD will remain @ Rs. 20,000/- per item of drug quoted subject to minimum of Rs. 2.00 lacs and maximum of Rs. 5.00 Lacs.
- (b) *The bidders shall submit/upload scanned copy of all the challans in Technical Bid deposited for Bid fees, RISL processing fee and Earnest Money, in case deposited in any branch of PNB throughout country. The required EMD / Tender fees/ RISL fee may be in form of physical D.D./ BC along with letter. D.D. / bankers cheque shall be in favour of M.D. RMSCL (tender fees and EMD), MD, RISL (tender procession fees) .*
- (c) **Those who wish to apply for Empanelment as supplier for drugs and medicines** are required to deposit separately an Empanelment Fee of Rs 5000 (Five Thousand rupees only) in the form of DD in favour of MD, RMSC before due time and date of bid submission.
- (d) Documentary evidence for the constitution of the company/Firm such as Memorandum and Articles of Association, Partnership Deed etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director/Partners/Proprietor.
- (e) The Bidder should furnish attested copy of the valid License for the product duly approved by the Licensing authority for each and every product quoted as per specification in the Bid. The license must have been duly renewed/ valid up to date and the items quoted shall be clearly highlighted (*Bid item codes marked against each item*) in the license.



- (f) Attested photocopy of the valid import license in Form 10 with Form 41 (as per Rule 122A of Drugs and Cosmetics Act), if the product is imported. The license must have been renewed /valid up to date. A copy of a valid license for the sale of Drugs imported by the firms issued by the licensing authority shall be enclosed.
- (g) The instruments such as power of attorney, resolution of board etc., authorizing an officer of the Bidder should be enclosed.
- (h) Authorization letter nominating a responsible person of the Bidder to transact the business with the Bid Inviting Authority ***with duly attested signature and photograph***
- (i) Market Standing Certificate issued by the Licensing Authority/ competent authority as a Manufacturer for the product for last 3 years (Certificate should be enclosed with list of items) should be enclosed. Items quoted should be highlighted in the market standing certificate. In the case of direct importer, evidence for importing the item for last three years will be produced. These may be bill of lading, bill of entry for last three years, or certificate of analysis done at importing cargo point in India.
- (j) Non-conviction Certificate issued by the Drugs Controller of the State. It should be recent and not more than one year old.
- (k) Good manufacturing practices Certificate (GMP) as per revised Schedule –'M', or WHO-GMP Certificate issued by the Licensing Authority. The GMP certificate must not be older than one year from the due date of Bid submission in the case where validity is not mentioned in the certificate. ***The Bidder shall also furnish an undertaking in the format given in Annexure-VII point no.8*** declaring that the Bidder complies with the requirements of GMP (as per revised Schedule-'M'). The Importer should produce WHO- GMP /COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries

like US- FDA approval, etc. In the case of imported drugs, labels and product literature of all quoted products must be submitted.

- (l) Annual turnover statement for 3 years i.e., 2009-10, 2010-11 and 2011-12 in the format given in Annexure-III certified by the practicing Chartered Accountant.
- (m) Copies of the Balance Sheet and Profit and Loss Account for three years i.e. 2009-10, 2010-11 and 2011-12 duly certified by the practicing Chartered Accountant.
- (n) VAT/Sales Tax Clearance certificate (copies of latest challans), as on 30.12.2012.
- (o) Registration with Excise Department, Govt. of India. The industries situated in excise free zones will be exempted from the registration provided they produce the copy of appropriate notification.
- (p) Undertaking (**as in Annexure-VII**) for embossment of logo on labels of bottles, etc as the case may be, as per conditions specified at Clause 14 herein.
- (q) Undertaking that the manufacturer has not been blacklisted, the product has not been declared as not of standard quality during last two years, it's manufacturing capacity and other details required on a format mentioned at Annexure-VII.
- (r) Details of technical personnel employed in the manufacture and testing of drugs (Employee Name, Qualification, and Experience) as enclosed in license.
- (s) List of items quoted to be shown in the Annexure-VII point **number 6**
- (t) A **Checklist (Annexure-V)** for the list of documents enclosed with their page number. The documents should be serially arranged as per **Annexure-V**. Every bidder will also be required to submit details of product permission of the quoted item and the desired market standing, **in Annexure- VI**

- (u) If a company has two or more separate manufacturing units at different sites/states, the company will be allowed to submit only one Bid for all units but necessary document regarding separate manufacturing units will be submitted as a separate set with the same Bid. But a bidder will be allowed to submit only one offer for one product.
- (v) An undertaking that the bidder complies with all the terms, conditions, amendments (if any) of bid document to be submitted in ***Annexure-VII point no.11.***
- (w) ***A declaration under Section 7 of Rajasthan Transparency in Public Procurement Act, 2012 in Annexure-VII point no. 13***
- (x) All copies submitted should be attested and notarized. However, scanned copies of original documents will be accepted which obviously need be notary attested.
- (y) An undertaking in ***Annexure-XI*** that the bidder wishes to get Empanelled as supplier for the quoted items and has submitted the necessary fee for the same. *(This is only for those who apply for empanelment also)*
- (z) ***A copy of PAN issued by Income Tax Department.***

**6. PRICE BID** – The price bid will also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). ***The bidder should quote rate for the mentioned packing unit only.***

## **7. OPENING OF TECHNICAL AND FINANCIAL BID**

The Bid will be scrutinized by Bid evaluation committee and inspection of manufacturing unit for compliance of GMP may be carried out by technical committee. Price Bid (BOQ) of the ***Bidder*** found eligible on satisfying the criteria for technical evaluation and inspection, will only be opened.

8. **EARNEST MONEY DEPOSIT**

The Earnest Money Deposit shall be @ **Rs. 20,000/- for each item of drug quoted subject to minimum of Rs. 2.00 lacs and maximum of Rs. 5.00 Lacs.** EMD will not be taken from undertakings, corporation of GoI & GoR. EMD will be taken @ Rs. 5,000/- per item of drug quoted subject to minimum of Rs. 50,000/- and maximum of Rs. 1.25 Lacs, from SSI Units of Rajasthan. *They will furnish copy duly attested by gazetted officer of the registration of SSI units issued by the Director of Industries in respect of the stores for which they are registered. Duly attested copy of Acknowledgement of EM-II issued by DIC with an affidavit worth Rs.10 as per Annexure-II under preference to Industries of Rajasthan rules 1995 in respect of stores for which they are registered. (Annexure-II).* In case Earnest money submitted by the bidder is at the minimum or more but number of quoted items is more than the earnest money submitted, the quoted items by the bidder will be counted in sequence up to the number matching the earnest money deposited. However without minimum earnest money the offer will not be considered at all. The Earnest Money Deposit shall be paid **in through separate prescribed challans (format enclosed in Annexure-I ) in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country upto 8.4.2013 or through D.D. / bankers cheque in favour of M.D. RMSCL physically in the office of RMSC by 1.00 PM on 09.04.2013. Earnest Money Deposit in any other form will not be accepted.**

The Bids submitted without sufficient EMD will be summarily rejected. The EMD will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails within specified time to sign the contract agreement or fails to furnish the security deposit.

9. **OTHER CONDITIONS**

1. The orders will be placed by the Managing Director or any officer designated, Rajasthan Medical Services Corporation Ltd, (hereinafter referred to as Ordering Authority).
2. The details of the required drugs, medicines, etc., are shown in **Annexure-VIII**. The quantity mentioned is only the tentative requirement and may increase or decrease as per the decision of Ordering Authority. The rates quoted should not vary with the quantum of the order or the destination.
3. Bid has been called for in the **generic names of drugs**. The Bidders should quote the rates for the generic products. The composition and strength of each product should be as per details given in **Annexure-VIII**. Any variation, if found, will result in rejection of the Bid. The products should conform to the specified standards IP/BP/USP. In case the product is not included in the said compendium, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing.
4. Rates (inclusive of Excise Duty, Customs duty, transportation, insurance, and any incidental charges, but exclusive of Sales tax) should be quoted for each of the required drugs, medicines etc., separately on door delivery basis according to the unit ordered. Bid for the supply of drugs, medicines, etc. with conditions like “AT CURRENT MARKET RATES” shall not be accepted. Handling, clearing, transport charges etc., will not be paid. The delivery should be made as stipulated in the purchase order placed with successful Bidders. No quantity or cash discount should be offered.
5.
  - a) To ensure sustained supply without any interruption, the Bid Inviting Authority reserves the right to fix more than one supplier to supply the requirement among the qualified Bidders
  - b) Orders will be placed periodically during rate contract period based on the stock positions only. Orders will be placed with L1 firms. However in order

to ensure regular supply in case of any exigency at the discretion of the Bid Inviting Authority, the orders may also be placed with the other firms, in the ascending order, L-2, L-3 and so on who have matched the L1 rates.

- c) After the conclusion of Price Bid opening, the lowest offer of the Bidder, if required will be considered for negotiations, and rate arrived after negotiations will be L-1 rate and L-1 supplier for an item of drugs/medicines for which the Bid has been invited.
- d) The Bidder who has been declared as L-1 supplier for certain item or items of drugs/medicines shall execute necessary agreement for the supply of the Bided quantity of such drugs/medicines as specified in the Bid document on depositing the required amount as performance security and on execution of the agreement, such Bidder is eligible for the placement of purchaser orders.
- e) RMSC will inform the L1 rate to the Bidders who qualified for Price Bid opening, **through RMSC web site or e-mail; willing bidders may inform in writing** their consent to match with the L-1 rate for the item of the Drugs/Medicines quoted by them and the Bidders who agree to match L1 rate, will be considered as Matched L1.
- f) The Bidder, who agrees to match L-1 rate shall furnish the breakup detail (Rate, CST, VAT etc.) of price (L-1 rate).
- g) The supplier upon receipt of the purchase order deems that the purchase orders exceeds the production capacity declared in the Bid documents and the delay would occur in executing the order, shall inform the RMSC immediately without loss of time and the purchase orders shall be returned within 7 days from the date of the order, failing which the supplier is estopped from disputing the imposition of liquidated damages, fine for the delayed supply.
- h) If the L1 supplier has failed to supply /intimated RMSC about his inability/delay in supply as per the purchase order, the required Drugs/ Medicines within the stipulated time or as the case may be, RMSC may also

place purchase orders with the Matched L1 Bidder for purchase of the Drugs/Medicines, provided such matched L1 Bidders shall execute necessary agreement indicating the production capacity as specified in the Bid document on depositing the required amount. Such Bidder is eligible for the placement of purchase orders for the item or items of Drugs/Medicines quoted by them.

- i) Subject to para (h) above, while RMSC has chosen to place purchase orders with Matched L1 supplier and there are more than one such matched L1 suppliers, then the purchase orders for the requirement of Drugs/Medicines will be placed with L-2 first on matched rates of L-1 and in case L-2 does not have the required capacity than L-3 would be considered on matched L-1 rates and the same order would be followed in case of L-3, L-4 etc.
  - j) The matched L1 supplier, on placement of purchase orders, will be deemed as L-1 rate supplier for the purpose of the Bid and all provisions of the Bid document applicable to L-1 rate Bidder will apply mutatis mutandis to the matched L1 supplier.
- 6. The rates quoted and accepted will be binding on the Bidder during validity period of the bid and any increase in the price (except increase due to Excise Duty or any other statutory taxes) will not be entertained.
  - 7. No Bidder shall be allowed at any time on any ground, whatsoever it may be, to claim revision or modification in the rates quoted by him after last date fixed for receipt of bid. Representation to make correction in the Bid documents on the ground of Clerical error, typographical error, etc., committed by the Bidders in the Bids shall not be entertained after submission of the Bids. Conditions such as “SUBJECT TO AVAILABILITY” “SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED” etc., will not be entertained under any circumstances and the Bids of those who have given such conditions shall be treated as incomplete and accordingly the Bid will be rejected.
  - 8. The rates should be quoted only for the composition stated in the Bid.

9. Supplies should be made directly by the bidder and not through any other agency.
10. The Bidder shall allow inspection of the factory at any time by a team of Experts/Officials of the Bid Inviting Authority and or of the Govt. of Rajasthan. The Bidder shall extend all facilities to the team to enable to inspect the manufacturing process, quality control measures adopted etc., in the manufacture of the items quoted. If a Company/Firm does not allow for any such inspection, its Bids will be rejected.

#### **10. ACCEPTANCE OF BID**

1. The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria.
2. Bid Inviting Authority reserves the right to accept or reject the Bid for the supply of all or any one or more items of the drugs Bided for in a Bid without assigning any reason.
3. Bid Inviting Authority, or his authorized representative (s) has the right to inspect the factories of Bidders, before, accepting the rate quoted by them, or before releasing any purchase order(s), or at any point of time during the continuance of Bid and also has the right to reject the Bid or terminate/cancel the purchase orders issued and or not to reorder, based on adverse reports brought out during such inspections.
4. The acceptance of the Bids will be communicated to the successful Bidders in writing by the Bid inviting authority. Immediately after receipt of acceptance letter, the successful Bidder will be required to deposit security deposit and agreement but not later than 10 days.
5. The **approved** rates of the successful Bidders would be valid for one year as Annual Rate contract, may extendable by 3 months with mutual consent.

#### **11. SECURITY DEPOSIT(PERFORMANCE GUARANTEE)**

The Successful Bidders shall be required to pay performance Security Deposit @ 5% of the Contract value. Performance security will not be taken from undertaking,



corporation of GoI & GoR. The SSI Units of Rajasthan shall be required to pay Performance security @ 1% of the contract value.

*The performance security shall have an upper limit of Rs 25 Lac to be deposited by a bidder at the time of signing of agreement (For one or many items). However, when the actual purchase orders cross a threshold for requiring additional security (for a period of 16 month), the same will be required to be deposited by the supplier.*

The performance security should be paid upfront in respect of each contract **on or before the due date fixed by Bid inviting authority in the form of Bank Guarantee in case the amount exceeds Rs 5 Lakhs. For amount of upto 5 Lakhs it should be deposited in the form of** demand draft/bankers cheque issued by a scheduled bank or may be deposited through challan annexure 1 **(the validity of bank guarantee should be for a period of sixteen month from the date of issuance of Bank Guarantee)** in favor of the Managing Director, Rajasthan Medical Services Corporation Ltd, Payable at Jaipur, viz. Bid inviting authority before releasing the purchase order by the ordering authority. In case L-2, L-3 and so on, bidders who have agreed to match L-1 price, then the EMD of L-2, L-3 and so on bidders will be converted *(Rs 20000/- per item)* into security deposit. In case of inability of L-1 bidder to supply the required quantity of drugs, in that case the L-2 and L-3 supplier (as the case may be) will be asked to supply the drugs. At the time of placing of order these matched suppliers will be asked to deposit amount of balance **security for a period of 16 month.**

## 12. **AGREEMENT**

- a) The successful Bidder shall execute an agreement on a non-judicial stamp paper of value mentioned in the Acceptance Letter (stamp duty to be paid by the Bidder) within 15 days from the date of the intimation letter of interest by the Bid Inviting Authority, viz., the **Managing Director, Rajasthan Medical Services Corporation Ltd.** The Specimen form of agreement is available in **Annexure-IV, failing to submission of performance security and execution of**

**agreement within 15 days as stipulated, will result in forfeiture of EMD & other consequential action.**

- b) The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any person or persons whatsoever.
- c) All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or left at the premises, places of business or abode.

13. **SUPPLY CONDITIONS**

- 1. Purchase orders along with the delivery destinations will be placed on the successful Bidder at the discretion of the Ordering Authority. Drugs and Medicines will be supplied at 33 Districts Head Quarters of Rajasthan (CM&HO & Medical Colleges Stores).
- 2. The supplier shall supply the entire ordered quantity before the end of 45 days from the date of issue of purchase order at the destinations mentioned in the purchase order, if the above day happened to be a holiday for RMSC, the supply should be completed by 5.00 p.m. on the next working day. For drug items requiring sterility test and imported ones, the supply period will be 60 days from the date of issue of purchase order.
- 3. All supplies will be scheduled for the period from the date of purchase order till the completion of the tender in installments, as may be stipulated in the purchase order.
- 4. **Shelf Life:** The labeled shelf life of drugs supplied should be not less than the period mentioned against each item in list of Drugs (Annexure-VIII). The remaining shelf life of the drugs at the time of delivery should not be less than  $\frac{3}{4}$  of the labeled shelf life. ***Only those bidders shall quote who can manufacture and supply the product with the required shelf life. The product of labeled shelf life lesser than required shelf life will not be accepted. The product should not have such storage condition requiring it to be stored below 2<sup>o</sup> C.***

5. Quality Assurance: The supplier shall guarantee that the products as packed for shipment (a) comply with all provisions of specifications and related documents (b) meet the recognized standards for safety, efficacy and quality; (c) are fit for the purpose made; (d) are free from defects in workmanship and in materials and (e) the product has been manufactured as per cGMP included in Schedule M of Drugs & Cosmetic Rules.
6. The protocol of the tests should include the requirements given in I.P for tablets and those required specifically for the product specifications. The Bidder must submit its Test/ Analysis Report for every batch of drug along with invoice. In case of failure on the part of the supplier to furnish such report, the batch of drugs will be returned back to the supplier and he is bound to replenish the same with approved laboratory test report. The supplier shall provide the validation data of the analytical procedure used for assaying the components and shall provide the protocols of the tests applied.
7. The Drugs and medicines supplied by the successful Bidder shall be of the best quality and shall comply with the specification, stipulations and conditions specified in the Bid documents.
8. If supplies are not fully completed in 45 days from the date of the Purchase Order (60 days for drugs of the category of serum, vaccine, enzymes, blood grouping reagents, biological products, powder for injections and imported drugs), the provisions of liquidated damages of Tender conditions will come into force. The Supplier should supply the drugs at the Warehouse specified in the Purchase Order and if the drugs supplied at a designated places other than those specified in the Purchase Order, transports charges will be recovered from the supplier.
9. If the supplier fails to execute at least 50% of the quantity mentioned in single purchase order and such part supply continues for three consecutive Purchase orders, then the supplier will be ineligible to participate in any of the Bids for

particular items of drugs/medicines for a period of one year immediately succeeding year in which supplier has been placed Purchase order.

10. If the Bidder fails to execute the supply within the stipulated time, the ordering authority is at liberty to make alternative purchase of the items of drugs and medicines for which the Purchase orders have been placed from any other sources or in the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the Ordering Authority/Bid inviting authority has every right to recover the cost and impose penalty as mentioned in Clause 19, apart from terminating the contract for the default.
11. The order stands cancelled after the expiration of delivery period, and if the extension is not granted with or without liquidated damages. Apart from risk/alternate purchase action, the Bidder shall also suffer forfeiture of the performance security and shall invite other penal action like blacklisting/Debarring disqualification from participating in present and future Bids of Bid Inviting Authority/ordering authority. . (As per guidelines for blacklisting/ debarring at annexure- IX including amendment)
12. It shall be the responsibility of the supplier for any shortage/damage at the time of receipt at the designated places.
13. If at any time the Bidder has, in the opinion of the ordering authority, delayed in making any supply by reasons of any riots, mutinies, wars, fire. storm, tempest or other exceptional cause on a specific request made by the Bidder within 7 days from the date of such incident, the time for making supply may be extended by the ordering authority at its discretion for such period as may be considered reasonable. The exceptional causes do not include the scarcity of raw material, Power cut, labour disputes.
14. The supplier shall not be in any way interested in or concerned directly or indirectly with, any of the officers, subordinates or servants of the Bid Inviting Authority in any trade or business or transactions nor shall the supplier give or

pay promise to give or pay any such officers, subordinates or servants directly or indirectly any money or fee or other considerations under designation of “Customs” or otherwise, nor shall the supplier permit any person or persons whom so ever to interfere in the management or performance hereof under the power of attorney or otherwise without the prior consent in writing of the Bidder Inviting Authority.

**15. The supplier of sevoflurane anesthetic (code no. 491) shall install vaporizers on loan basis free of cost, in required numbers, as per the need of the Healthcare facilities/ institutions.**

**14. LOGOGRAMS /Markings**

Logogram means, wherever the context occurs, the design as specified below:-


**DESIGNS FOR LOGORAMS**

**INJECTIONS**

Injection in ampoule form should be supplied in Double constructed neck ampoules with the lable bearing the words “**Rajasthan Govt. Supply- Not for sale निःशुल्क वितरण हेतु, QC – Passed**” overprinted and the following logogram which will distinguish from the normal trade packing. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.



The vials should be supplied with aluminum seals containing the following logogram:



## LIQUIDS

Liquid preparations should be in bottles with pilfer-proof caps bearing the following logogram:




The top of the cap and the label to be affixed on the containers should bear a distinct colour different from the colour of the label of the trade packs and they should be overprinted in red colour with the words **“Rajasthan Govt. Supply- Not for Sale निःशुल्क वितरण हेतु, QC – Passed”** and the logogram. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.




## OINTMENTS & CREAMS

Ointments & Creams should be supplied in tubes bearing the following logograms and the words **“Rajasthan Govt. supply- Not for sale निःशुल्क वितरण हेतु, QC – Passed”** overprinted. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.



## TABLETS & CAPSULES

Tablets and Capsules should be supplied in Strips or Blisters or as mentioned in the list of items for tender. The strip, etc, should bear the following logograms and the words **“Rajasthan Govt. supply- Not for sale निःशुल्क वितरण हेतु, QC – Passed”** overprinted. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.



-

SPECIMEN LABEL FOR OUTER CARTON  
SHALL BE OF DIFFERENT COLOURS FOR DIFFERENT CLASS  
OF DRUGS

**RAJASTHAN GOVT. SUPPLY  
NOT FOR SALE**

---

**(Name of Drugs etc.)**

---

CONSTITUENTS OF.....

Name of the Drug, Manufactured by, Batch no

Mfg.Date, Exp. Date, Quantity/Kit

Net. Weight:.....Kg

Manufactured by/Assembled by



-

The name of the drug shall be mentioned in Hindi and English and should be legible and be printed more prominently. **A uniform colour theme and artwork will be necessary.** Apart from this “**For Govt. of Rajasthan – Not for Sale निःशुल्क वितरण हेतु, QC – Passed**” alongwith logo of RMSCL will be printed on each strip/label of the bottle. The storage directions should be clear, legible and preferably with yellow highlighted background.

1. Bids for the supply for Drugs and medicines etc., shall be considered only if the Bidder gives undertaking in his Bid that the supply will be prepared and packed with the logogram printed on the strips of tablets and capsules and labels of bottles, ampoules and vials etc., as per the design mentioned above.
2. All tablets and capsules have to be supplied in standard packing in aluminum strip or blisters with aluminium foil back with printed logogram and shall also conform to schedule P1 of the Drugs & Cosmetics Act & Rules wherever it applies. Affixing of stickers and rubber stamps shall not be accepted.
3. Labels of Vials, Ampoules and Bottles containing the items Bided for should also carry the logogram.
4. Failure to supply Drugs etc., with the logogram will be treated as breach of the terms of agreement and liquidated damages will be deducted from bills payable as per conditions in Clause 18.2 Bidders who are not willing to agree to conditions above will be summarily rejected.
5. In case of imported drugs affixing rubber stamp on the original label is allowed with indelible ink on inner most and outer packing.

## 15 **PACKING**

1. The item shall be supplied in the package schedule given below and the package shall carry the logogram specified in clause -14. The labeling of different packages should be as specified below. The packing in each carton shall be

strictly as per the specification mentioned. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties.

2. The pediatric drops should always be supplied with dropper. A measuring cap with suitable markings must be provided for other paediatric oral liquid preparations.
3. The labels in the case of injectables should clearly indicate whether the preparations are meant for IV, IM, SC, etc.
- 4. Injection vials should have flip off seals.**
- 5. All plastic containers should be made of virgin grade plastic.**
- 6. The name of the drug should be printed in clearly legible bold letters (It is advisable that the colour of font be different from other printed matter to make the name highly conspicuous.**
7. It should be ensured that only first hand fresh packaging material of uniform size is used for packing. All packaging must be properly sealed and temper proof.
8. All packing containers should strictly conform to the specifications prescribed in the relevant pharmacopoeia/Act.
9. Packing should be able to prevent damages or deterioration during transit.
10. In the event of items supplied found to be not as per specifications in respect of their packing, the Ordering Authority is at liberty to make alternative purchase of the item for which the purchase orders have been placed from any other sources or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier. In such cases the ordering authority has every right to recover the cost and impose penalty as mentioned in Clause 18.2 and 19.

## **I. SCHEDULE FOR PACKAGING OF DRUGS AND MEDICINES GENERAL SPECIFICATIONS**

No corrugate package should weigh over 15 kgs (i.e. product + inner carton + corrugated box).

All items should be packed only in first hand strong boxes only.

-

Every corrugated box should preferably be of single joint and not more than two joints.

Every box should be stitched using pairs of metal pins with an interval of two inches between each pair.

The flaps should uniform meet but should not overlap each other. The flap when turned by 45-60 should not crack.

Every box should be sealed with gum tape running along the top and lower opening.

#### **CARRY STRAP:**

Every box should be strapped with two parallel nylon carry straps (they should intersect.)

#### **LABEL:**

Every corrugated box should carry a large outer label clearly indicating that the product is for “Rajasthan Govt. Supply-Not for Sale”.

The Product label on the cartoon should be large, atleast 15 cms x 10 cms dimension. It should carry the correct technical name, strength or the product, date of manufacturing, date of expiry quantity packed and net weight of the box.

#### **OTHERS:**

NO box should contain mixed products or mixed batches of the same product.

### **II. SPECIFICATION FOR CORRUGATED BOXES HOLDING TABLETS/CAPSULES/PESSARIES**

1. The total weight of the box should be approx of 7-8 Kgs.

### **III. SPECIFICATION FOR LARGE VOLUME BOTTLE i.e., ABOVE 100 ml AND BELOW 1 LIT.**

1. All these bottles should be packed only in single row with partition between each and also with top and bottom pad of 3 ply.

### **IV. SPECIFICATION FOR IV FLUIDS**

Each corrugated box may carry maximum of only 24 bottles of 500 ml in a single row or 50 bottles of 100 ml in 2 rows with individual sealed polythene cover and centre partition pad, top and bottom pads of 3 ply.

## **V. SPECIFICATION FOR LIQUID ORALS**

100 bottles of 50 ml or 60 ml may be packed in a single corrugated in 2 rows with top, bottom and centre pad of 3 ply.

50 bottles of 100 ml – 120 ml may be packed in a similar manner in a single corrugated box.

If the bottles are not packed in individual carton, 3 ply partition should be provided between each bottle. The measuring device should be packed individually.

## **VI. SPECIFICATION FOR OINTMENT/CREAM/GELS PACKED IN TUBES:**

No corrugated box should weigh more than 7-8 Kgs.

Every Ointment tube should be individually packed in cartoon and then packed in 20's in a grey board box] which may be packed in a corrugated box.

## **VII. SPECIFICATIONS FOR INJECTION (IN VIALS AND AMPOULES)**

Vials may be packed in corrugated boxes weighing upto 15 Kgs. Ampoules should be packed in C.B weighing not more than 8 Kgs.

In the case of 10 ml Ampoules or 50 ampouls may be packed in a grey board box. Multiples of grey board boxes packed in CB. In case of ampoules larger than 10 ml only 25 ampoules may be packed in a grey board box with partition.

If the vial is packed in individual cartoon, there is no necessity for grey board box packing. The individual cartoon may be packed as such in the CB with centre pad.

In case of ampoules every grey board box should carry 5 amps alongwith Cutters placed in a polythene bag.

Vials of eye and ear drops should be packed in a individual cartoon with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a grey board box.

## **VIII. SPECIFICATION FOR ORS**

The sachets should be of Aluminium Foil laminated with glassin or heat sealable plastic film, Outer paper may contain label information.

50 sachets may be packed in grey board boxes and 10 grey board boxes in a C.B.

## **IX. LYSOL**

Not more than four 5 liters cans may be packed in a single Box.

16. **QUALITY TESTING**

1. Sampling of supplies from each batch will be done at the point of supply or distribution/storage points for testing. (The samples would be sent to different empanelled laboratories for testing by the ordering authority after coding). The RMSC will deduct a sum of 1.5% from the amount of bill payable to supplier on account of handling and testing charges.
2. The Drugs shall have the active ingredients within the permissible level throughout the shelf life period of the drug. The samples may also be drawn periodically during the shelf life period. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirements shall render the relevant batches liable to be rejected. If the sample is declared to be Not of Standard Quality or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.
3. In the event of the samples of the Drugs and medicines supplied failing quality tests or found to be not as per specification the ordering authority is at liberty to make alternative purchase of items of drugs and medicines for which the Purchase orders have been placed from any other sources or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the ordering authority has every right to recover the cost and impose penalty as mentioned in Clause 19.
4. The supplier shall furnish to the purchaser the evidence of bio-availability and/or bio-equivalence for certain critical drugs when asked for. If there is any problem in the field the B.M.R/B.P.R for the particular batch shall also be supplied when demanded.
5. The products should conform to the standards of IP/BP / USP as the case may be. In case the product is not included in the said compendium, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing. For imported drugs respective countries pharmacopeia standards shall be acceptable (even if the product is official in IP)

17. **PAYMENT PROVISIONS**

1. No advance payment towards costs of drugs, medicines etc., will be made to the Bidder.
  2. On receipt of the prescribed invoice, and RMSC analytical laboratory report regarding quality, the payment would be made in 30 days.
  3. The in charge of district drug ware house will be required to acknowledge the drugs received & ensure entry in e- Aushdhi software online. .
  4. All bills/ Invoices should be raised in duplicate and in the case of excisable Drugs and Medicines, the bills should be drawn as per Central Excise Rules in the name of the authority as may be designated. The supplier will deliver following document at the time of delivery at DDW.
    - a. In house test report of drug.
    - b. The challan / invoice copy pertaining to DDW
  5. Payments for supply will be considered only after supply of 70% of items of Drugs ordered in the Purchase Order .However, the payment will be released only for the quantity in case of which the quality test report from approved test laboratories of RMSC has been received and found of standard quality.
  6. If at any time during the period of contract, the price of Bided items is reduced or brought down by any law or Act of the Central or State Government or by the Bidder himself, the Bidder shall be bound to inform ordering authority immediately about it. Ordering authority empowered to unilaterally effect such reduction as is necessary in rates in case the Bidder fails to notify or fails to agree for such reduction of rates.
- 7(a) In case of any enhancement in Excise Duty due to notification of the Government after the date of submission of Bids and during the Bid period, the quantum of additional excise duty so levied will be allowed to be charged extra as a separate item without any change in the basic of the price structure price of the Drugs approved under the Bid. For claiming the additional cost on account of the increase in Excise Duty, the Bidder should produce a letter from the concerned

Excise authorities for having paid additional Excise Duty on the goods supplied to ordering authority and also must claim the same in the invoice separately.

Similarly if there is any reduction in the rate of essential drug, as notified by the Govt., after the date of submission of Bid, the quantum of the price to the extent of reduction of essential drug will be deducted without any change in the basic price of the price structure of the drugs approved under the Bid.

7(b) In case of successful bidder has been enjoying excise duty exemption on any criteria of Turnover etc., such bidder will not be allowed to claim excise duty at later point of time, during the tenure of contract, when the excise duty is chargeable on goods manufactured.

8. (i) If the supplier requires an extension in time for completion of contractual supply, on account of occurrence of any hindrance he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of completion of supply.

(ii) The purchase Officer may extend the delivery period with or without liquidated damages in case they are satisfied that the delay in the supply of goods is on account of hindrances. Reasons shall be recorded.

(iii) **Extension in delivery period:-** In case of extension in the delivery period with liquidated damages the recovery shall be made on the basis of following percentages of value of stores which the Bidder has failed to supply:-

- a) Delay upto one fourth period of the prescribed delivery period; 2.5%
- b) Delay exceeding one fourth but not exceeding half of the prescribed delivery period; 5%
- c) Delay exceeding half but not exceeding three fourth of the prescribed delivery period; 7.5%
- d) Delay exceeding three fourth of the prescribed delivery period. 10%

Note: Fraction of a day in reckoning period of delay in supplies shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.

9. If, at any time during the continuance of this Agreement, the Supplier has, in the opinion of the Purchaser, delayed in making any supply ordered, by the reasons of any riots, mutinies, wars, fire, storm, tempest or other exceptional cause, on a specific request made by the Supplier, the time for effecting delivery may be extended by the Purchaser solely at his discretion for such period as may be considered reasonable by the Purchaser. No further representation from the Supplier will be entertained on this account.

18. **DEDUCTION IN PAYMENTS:**

1. If the supply is received in damaged conditions it shall not be accepted.
2. All the Bidder are required to supply the product with logogram and with prescribed packing specification. If there is any deviation in these Bid conditions a separate damages will be levied @ 2% irrespective of the ordering authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause **No.15.7.**

19. **QUALITY CONTROL DEDUCTION&OTHER PENALTIES:**

1. If the successful Bidder fails to execute the agreement and/or to deposit the required performance security within the time specified or withdraws his Bid after the intimation of the acceptance of his Bid has been sent to him or owing to any other reasons, he is unable to undertake the contract, his contract will be cancelled and the Earnest Money Deposit deposited by him along with his Bid, shall stand forfeited by the Bid Inviting Authority and he will also be liable for all damages sustained by the Bid Inviting Authority apart from **blacklisting/ debarring the supplier.** (As per guidelines for blacklisting/ debarring at annexure IX including amendment)
2. If the samples drawn from supplies do not conform to statutory standards, the supplier will be liable for relevant action under the existing laws and the entire stock in such batch should be taken back by the supplier within a period of 30 days from the issue of letter from ordering authority the information of which may be communicated by e- mail. The stock shall be taken back at the expense of the supplier. Ordering authority has the right to destroy such NOT OF



STANDARD DRUGS IF THE SUPPLIER does not take back the goods within the stipulated time. Ordering authority will arrange to destroy the NOT OF STANDARD drugs within 90 days after the expiry of 30 days mentioned above, without further notice, and shall also collect demurrage charge calculated @ 2% per week on the value of the drugs rejected till such destruction.

3. The supplier will not be entitled to any payment whatsoever for Items of drugs found to be of NOT OF STANDARD QUALITY whether consumed or not consumed and the ordering authority is entitled to deduct the cost of such batch of drugs from the any amount payable to the Bidder. On the basis of nature of failure, the product/supplier will be moved for Black Listing. (As per guidelines for blacklisting/ debarring at annexure IX including amendment)
4. For supply of drugs of NOT OF STANDARD QUALITY the respective Drugs Controller will be informed for initiating necessary action on the supplier and that the report of product shall be sent to the committee for appropriate action including blacklisting. (As per guidelines for blacklisting/ debarring at annexure IX including amendment)
5. The decision of the ordering authority or any Officer authorized by him as to the quality of the supplied drugs, medicines etc., shall be final and binding.
6. Ordering Authority will be at liberty to terminate without assigning any reasons thereof the contract either wholly or in part on 30 days notice. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.
7. For infringement of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the ordering authority, and the supplier shall be liable for all losses sustained by the ordering authority, in consequence of the termination which may be recovered personally from the supplier or from his properties, as per rules.
8. Non performance of any contract provisions shall be examine and may disqualify the firm to participate in the future Bids.

9. In the event of making **ALTERNATIVE PURCHASE**, as specified in Clause **13.10, Clause 15.7 and in Clause 16.3** the penalty will be imposed on supplier apart from forfeiture of Security Deposit. The excess expenditure over and above contracted process incurred by the ordering authority in making such purchases from any other sources or from the open market or from any other Bidder who has quoted higher rates and other losses sustained in the process, shall be recovered from the performance security or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier.
10. In all the above conditions, the decision **of the Bid Inviting Authority, viz Managing Director, Rajasthan Medical Services Corporation Ltd, would be final and binding**, in case of any dispute regarding all cases under Bid procedure or in any other non-ordinary situation and would be acceptable to all.
11. All litigations related to the supplier for any defaults will be done by Bid Inviting Authority and his decision will be final and binding.

## **20. EMPANELMENT OF FIRMS**

**RMSC invites Applications from eligible firms for Empanelment for supply of Drug and Medicines mentioned in Annexure- VII for one year. The empanelment would entitle a firm to participate in RMSC limited tenders. Such situations may normally arise when the open tender for a Drug fails and there is an urgency to purchase it, or when the L-1 bidder has fail to supply, or the rate contract of an item ceases to exist for any reason. The Bidder has to submit an undertaking in the format given at Annexure-XI.**

**The empanelment can be renewed for the next one year term on payment of the empanelment fee as decided later on.**

21. **SAVING CLAUSE**

No suit, prosecution or any legal proceedings shall lie against Bid Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of Bid.

22. **JURISDICTION**

In the event of any dispute arising out of the Bid or orders such dispute would be subject to the jurisdiction of the Courts of Jaipur or Honorable High Court (Jaipur Bench **only**).

23. **CORRECTION OF ARITHMETIC ERRORS:**

*Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:*

*(i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;*

*(ii) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.*

*(iii) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.*

*If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.*

**24. PROCURING ENTITY'S RIGHT TO VARY QUANTITY:**

- (i) At the time of award of contract, the quantity of goods, originally specified in the bidding documents may be increased or decrease. There will not be any minimum quantity guaranteed against bid quantity.*
- (ii) If the procuring entity does not procure any subject matter of procurement or procures less than the quantity specified in the bidding documents due to change in circumstances, the bidder shall not be entitled for any claim or compensation except otherwise provided in the conditions of contract.*
- (iii) However a bidder is bound to supply up to approximate quantity indicated in bid document, considering the total production capacity & capacity dedicated to RMSC.*

**25. DIVIDING QUANTITIES AMONG MORE THAN ONE BIDDER AT (IN CASE OF PROCUREMENT OF GOODS):**

*As a general rule all the quantities of the subject matter of procurement shall be procured from the bidder, whose bid is accepted and declared successful L-1 bidder. However, when the quantity of drugs the subject matter of procurement is very large may not be in the capacity of the bidder, whose bid is accepted, to deliver the entire quantity of drugs or when it is considered that the drugs being of critical and vital nature, in such cases, the quantity of drugs may be divided between the bidders, whose bid are accepted and the second lowest bidder or even more bidders in that order.*

**26. GRIEVANCE REDRESSAL DURING PROCUREMENT PROCESS:**

*The Designation and address of the First Appellate Authority is\_ Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan.*

*The Designation and address of the Second Appellate Authority is Principal Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan and Chairman, RMSCL.*

*i. Filling an appeal*

*If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:*

*Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings:*

*Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.*

*ii. The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.*

*iii. If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of receipt of the order passed by the First Appellate Authority, as the case may be.*

*iv. Appeal not to lie in certain cases*

*No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-*

- (a) Determination of need of procurement;*
- (b) Provision limiting participation of Bidders in the Bid process;*
- (c) The decision of whether or not to enter into negotiations;*
- (d) Cancellation of a procurement process;*
- (e) Applicability of the provisions of confidentiality.*

*v. Form of Appeal*

*(a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.*

*(b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.*

*(c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorised representative.*

*vi. Fee for filling appeal*

*(a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.*

*(b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.*

*vii. Procedure for disposal of appeal*

*(a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.*

*(b) On the date fixed for hearing, the First Appellate Authority or Second Appellate*

*Authority, as the case may be, shall,-*

*(i) Hear all the parties to appeal present before him; and*

*(ii) Peruse or inspect documents, relevant records or copies thereof relating to the matter.*

*(c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.*

*(d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.*

## **27. COMPLIANCE WITH THE CODE OF INTEGRITY AND NO CONFLICT OF INTEREST:**

*Any person participating in a procurement process shall-*

*a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;*

*b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;*

*c) Not indulge in any collusion, Bid rigging or any-competitive behaviour to impair the transparency, fairness and progress of the procurement process;*

*d) Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;*

*e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;*

*f) Not obstruct any investigation or audit of a procurement process;*

*g) Disclose conflict of interest, if any; and*

*h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.*

***Conflict of interest:-***

***The Bidder participating in a bidding process must not have a Conflict of Interest.***

***A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.***

***I. A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:***

***a. Have controlling partners/shareholders in common; or***

***b. Receive or have received any direct or indirect subsidy from any of them; or c.***

***Have the same legal representative for purposes of the Bid; or***

***d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or***

***e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or***

***f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or***

***g. Bidder or any of its affiliates has been hired (or is proposed to be hired) by the Procuring Entity as engineer-in-charge/ consultant for the contract.***

**Managing Director  
Rajasthan Medical Services Corporation**





Format of Affidavit  
(On Non Judicial Stamp Paper of Rs. 10/-)

I.....S/o.....Aged.....Yrs..... residing  
at.....Proprietor/Partner/Director of M/s.....do  
hereby solemnly affirm and declare that:

(a) My/Our above noted enterprises M/s..... has been  
issued acknowledgement of Entrepreneurial Memorandum Part-II by the Districts  
Industries Center.....The acknowledgement No.  
is.....dated.....and has issued for Manufacture of  
following items.

- (i)
- (ii)
- (iii)
- (iv)
- (v)

(b) My/Our above noted acknowledgement of Entrepreneurial Memorandum Part-II has not been cancelled or withdrawn by the Industries Department and that the enterprise is regularly manufacturing the above items.

(c) My/Our enterprise is having all the requisite plant and machinery and is fully equipped to manufacture the above noted items.

Place.....

Signature of Proprietor/Director  
Authorized Signatory with Rubber  
Stamp and date

VERIFICATION

I.....S/o.....Aged.....Yrs...  
.....residing at.....Proprietor/Partner/Director of  
M/s.....verify and confirm that the contents at (a), (b) &  
(c) above are true and correct to the best of my knowledge and nothing has been  
concealed therein. So help me God.

DEPONENT

**ANNUAL TURN OVER STATEMENT**

The Annual Turnover (*for drugs and medicines including Surgical and sutures Business*) of M/s. \_\_\_\_\_ for

the past three years are given below and certified that the statement is true and correct.

Sl.NO.	Years	Turnover in Lakhs(Rs)
1.	2009-10	-
2.	2010-11	-
3.	2011-12	-
Total -		Rs. _____ Lakhs
Average turnover per annual	-	Rs. _____ Lakhs

Date:

Seal:

Signature of Auditor/  
Chartered Accountant  
(Name in Capital)

**AGREEMENT**

This Deed of Agreement is made on this \_\_\_\_\_ day of \_\_\_\_\_ 2013 by M/s. \_\_\_\_\_ represented by its Proprietor/Managing partner/Managing Director having its Registered Office at \_\_\_\_\_ and its Factory Premises at \_\_\_\_\_

(hereinafter referred to as “Supplier” which term shall include its successors, representatives, heirs, executors and administrators unless excluded by the Contract) on one part and Rajasthan Medical Services Corporation Ltd, represented by its Executive Director (P) having is office at Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur (hereinafter referred to as “The Purchaser” which term shall include its successors, representatives, executors assigns and administrator unless excluded by the Contract) on the other part.

Where as the Supplier has agreed to supply to the Purchaser, the Drugs and Medicines with specifications mentioned in the Schedule attached here to at the prices noted there in and in the manner and under the terms and conditions here in after mentioned and where as the Supplier has deposited with the Purchaser a sum of Rs \_\_\_\_\_ (Rupees only) as Security Deposit for the due and faithful performance of this Agreement, to be forfeited in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,

1. The term “Agreement”, wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to Bid floated for the supply cum rate contract of Iron And Folic Acid Suspension For Rajasthan Medical Services Corporation, the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.
2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  
(b) This Agreement shall be deemed to have come into force with effect from the \_\_\_\_\_ and it shall remain in force upto - \_\_\_\_\_.  
(c) The Bid quantity noted against each item in the schedule attached hereto indicates only the probable total requirements of the Purchaser in respect of each item for the Agreement Period indicated in Clause (b)

above. This quantity may increase or decrease at the discretion of the Purchaser. The Supplier shall make supplies of the Drugs and Medicines on the basis of the Purchaser Orders placed on him from time to time by the ordering Authorities of the purchaser specifying the quantities required to be supplied required to be supplied at the specific location in the state of Rajasthan.

#### **TERMINATION OF CONTRACT ON BREACH OF CONDITION**

- 1 (a) In case the Supplier fails or neglects or refuse to faithfully perform any of the Covenants on his part herein contained, it shall be lawful for the Purchaser to forfeit the amount deposited by the Supplier as Security Deposit and cancel the Contract.  
(b) In case the Supplier fails, neglects, or refuse to observe, perform, fulfill and keep, all or any one or more or any part of any one of the Covenants, stipulation and provisions herein contained, it shall be lawful for the Purchaser on any such failure, neglect or refusal, to put an end to this Agreement and thereupon every article, cause and thing herein contained on the part of the Purchaser shall cease and be void, and in case of any damage, loss, expenses, difference in cost or other moneys from out of any moneys for the time being payable to the Supplier under this and/or any other Contract and in case such last mentioned moneys are insufficient to cover all such damages, losses, expenses, difference in cost and other moneys as aforesaid, it shall be lawful for the Purchaser to appropriate the Security Deposit made by the Supplier as herein before mentioned to reimburse all such damages, losses, expenses, difference in cost and other money as the Purchaser shall have sustained, incurred or been put to by reason of the Supplier having been guilty of any such failure, negligence or refusal as aforesaid or other breach in the performance of this Contract.  
(c) If at any time during the course of the Contract, it is found that any information furnished by the Supplier to the Purchaser, either in his Bid or otherwise, is false, the Purchaser may put an end to the Contract/Agreement wholly or in part and thereupon the provisions of Clause (a) above shall apply.
- 2 The Purchaser reserves the right to terminate without assigning any reasons therefore the Contract/Agreement either wholly or in part without any notice to the Supplier. The Supplier will not be entitled for any compensation whatsoever in respect of such termination of the Contract/Agreement by the Purchaser.

#### **NOTICE ETC, IN WRITING**

- 3 All Certificates or Notice or orders for time or for extra, varied or altered supplies which are to be the subject of extra or varied charges whether so described in the Agreement or not, shall be in writing, and unless in writing, shall not be valid, binding or be of any effect whatsoever.

#### **SUPPLIERS NOT HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATES**

- 4 The Supplier shall not be in any way interested in or concerned directly or indirectly with, any of the Officers, Subordinate or Servants of the Purchaser. In

-  
any trade, business or transactions nor shall the Supplier give or pay or promise to give or pay any such Officer, Subordinate or Servant directly or indirectly any money or fee or other consideration under designation of "Custom" or otherwise; nor shall the Supplier permit any person or persons whomsoever to interfere in the management or performance hereof under power of attorney or otherwise without the consent in writing the consent in writing of the Purchaser obtained in first hand.

### **BANKRUPTCY OF THE SUPPLIER**

- 5 In case the Supplier at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of bankruptcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the Purchaser to put an end to the Agreement, and thereupon every article, clause and thing herein contained to be operative on the part of the Purchaser, shall cease and be void and the Purchaser shall have all the rights and remedies given to him under the preceding clauses.

### **SERVING OF NOTICE ON SUPPLIER**

- 6 All notice or communication relating to or arising out of this Agreement or any of the terms thereof shall be considered duly served on or given to the Supplier if delivered to him or left at his premises, place of business or abode.
- 7 And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any of clause herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of the Managing Director, Rajasthan Medical Services Corporation Ltd in the matter shall be final and binding.
- 8 All disputes arising out of this agreement and all questions relating to the interpretation of this agreement shall be decide by the Govt. and the decision of the Govt. shall be final.

SUPPLIER

EXECUTIVE DIRECTOR (P),  
RAJASTHAN MEDICALSERVICES CORPORATION LTD.

Witness

Witness

1.

2.

-  
ANNEXURE – V  
Ref. Clause No. 5 (r)

COVER – A

**PAGE NO:**

1. Checklist – Annexure -V

	Yes		No	
--	-----	--	----	--

2. Challan of EMD, tender fee and RISL fee and SSI certificate for exemption with Annexure-II

	Yes		No	
--	-----	--	----	--

3. Documentary evidence for the constitution of the company / concern

	Yes		No	
--	-----	--	----	--

4. Duly attested copy of manufacturing License and its renewal/ validity certificate

	Yes		No	
--	-----	--	----	--

5. Duly attested copy of Product Permissions by the Licensing Authority for each and every product quoted

	Yes		No	
--	-----	--	----	--

6. Duly attested copy of Import License, if imported.

	Yes		No	
--	-----	--	----	--

7. Duly attested copy of Sale License, in the case of imported drugs.

	Yes		No	
--	-----	--	----	--

8. The instruments such as power of attorney, resolution of board etc.

	Yes		No	
--	-----	--	----	--

9. Authorization letter nominating as responsible person of the Bidder to transact the business with Bid inviting Authority

	Yes		No	
--	-----	--	----	--

10. Market Standing Certificate issued by the licensing Authority

	Yes		No	
--	-----	--	----	--

11. Copy of record of import to establish 3 years market standing.

	Yes		No	
--	-----	--	----	--

12. Non Conviction Certificate issued by the Drugs Controller

	Yes		No	
--	-----	--	----	--

13. Good Manufacturing Practices Certificate

	Yes		No	
--	-----	--	----	--

14. Annual Turnover Statement for 3 Years  
(Annexure-III)

	Yes		No	
--	-----	--	----	--

15. Copies of balance sheet & profit loss  
account for three years

	Yes		No	
--	-----	--	----	--

16. Sales Tax clearance certificate

	Yes		No	
--	-----	--	----	--

17. Excise Registration Certificate

	Yes		No	
--	-----	--	----	--

18. Declaration and Undertaking  
(Annexure –VII )

	Yes		No	
--	-----	--	----	--

19. Details of product permission  
and market standing (Annexure- VI )

	Yes		No	
--	-----	--	----	--

20. Under taking for empanelment  
(Annexure-XI)

	Yes		No	
--	-----	--	----	--

-

Check list of details regarding products quoted  
Annexure – VI  
Clause 5 (r)

Product permission as per condition no. 5 (c) and Market Standing as per condition 5 (g)									
Sr. No.	Quoted Item / Code no.	Product permission enclosed on page no.	Date of product permission / Approval	Product permission of formulation / Generic / Branded	Specification as per Code no. Yes/ No	As per MSC product Mfg & Mkd since last 3 years		Attested	Remarks
						Page No.	Yes/ No		
1									
2									
3									
4									
5									



-  
**Annexure – VII**  
**Clause 5 (i),(n),(o),(q),(t),(u)**

***Declaration & Undertaking***  
***(for F.02(42)/RMSCL /procurement/drug/nit-1/2013/281Dated 26.2.2013)***  
***(On Non-Judicial Stamp Paper of Rs 500/- Attested by Notary Public)***

I Name.....S/o.....Age.....Prop./Partner/Director/Power of attorney holder of firm M/s.....situated at (Complete address of Mfg. unit).....bearing drug license on Form 25 & 28 bearing Number..... &.....respectively, issued on dated.....valid/Renewed up to.....do here by declare on oath as follows:-

1. That none of the quoted Drug and Medicines manufactured by us since grant of above drug license have been found as of spurious or adulterated quality and no case in this regard is pending in any court.
2. That the quoted product is manufactured/imported by us, and none has been declared as “Not of standard quality” during last two years.
3. That we have following installed manufacturing capacity in our plant at above address:-

S.No.	Category [Tab/Cap/Liquid/ /injectable/ointment (Tubes) etc]	Oral	<i>Spare dedicated manufacturing capacity for RMSC per month (irrespective of number of shifts)</i>

4. That our Firm/Company does not stand blacklisted/debarred or banned by any State or Central Government or by its drug procurement agencies, on the date of bid submission for supply of drugs/medicines in India.
5. That our Firm/Company and its Proprietor/Partner/Directors/ Power of attorney holders have not been convicted for contravention of any

provisions of Drugs & Cosmetic Act 1940 and rules made there under since grant of license.

6. That we have been granted product permission by the State Licensing Authority for manufacture of quoted products as per the details given below:-

<i>S. No.</i>	<i>Code No.</i>	<i>Name of the Product</i>	<i>Specification IP/BP/USP/ Other</i>	<i>Date of product permission obtained from the Licensing Authority</i>	<i>Whether Endorsement is in Generic or Trade Name</i>	<i>Issuing Licensing Authority</i>
<i>1.</i>						

7. That we have over three years' experience in the manufacture of the quoted product.
8. That we have approved qualified staff, machines & equipments along with capacity to manufacture above category of drugs and our unit have been issued G.M.P.\* Certificate as per Schedule M by State Licensing Authority vide letter No.....dated.....valid upto.....
9. That we hereby confirm that we have deposited all the VAT/Sale Tax as on.....With the department No VAT/CST is due on M/s.....as on.....
10. That I will supply the Drug and Medicines per the designs **given in Bid clause no 14 and** as per the instructions given in this regard.
11. That I/We have carefully read all the conditions of Bid in Ref.no. F.02(42)/RMSCL/PROCUREMENT/DRUG/NIT-1/2013/281 dated 26.2.2013 for supply Cum rate contract of Drug and Medicines For Rajasthan Medical Services Corporation and accept all conditions of Bid, including amendments if any.

-

**12.**I/We agree that the Bid Inviting Authority forfeiting the Earnest Money Deposit and or Security Deposit and blacklisting /Debarring/Banning me/us for a period of 5 years or as deemed fit if, any information furnished by us proved to be false/fabricated at the time of inspection and not complying the conditions as per Schedule M of the said Act ***or at any time during the Bid process.***

13..... I/ we hereby declare under Section 7 of Rajasthan Transparency in Public Procurement Act, 2012. that:

- a. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;
- b. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the State Government or any local authority as specified in the Bidding Document;
- c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;
- d. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;
- e. I/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition;

14. Our complete address for communication:- \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

15. E=mail address :- \_\_\_\_\_

(Name of Deponent & Signature)  
Designation

-

**Verification**

I.....S/o.....(Designation).....

Affirm on oath that the contents/information from para 1 to 15 as mentioned above, are true & correct to the best of my knowledge and nothing is hidden. I also declare on oath, that if any information furnished by me as above is found wrong, false, forged or fabricated; the Corporation will be at liberty to cancel the Bid for which I shall be solely responsible and the firm may be Debarred/Banned/blacklisted / prosecuted for the same

(Name of Deponent & Signature)

Witness :- (Name, Address & Signature)

1

2

\*The GMP certificate must not be older than one year from the last date of Bid submission in case validity is not mentioned in the certificate.

## List of Drugs with Specifications

S. No.	Code No.	Name of item with sepcification	Packing Unit	Estimated Tender Qty.(No. of tabs, Caps, ampoules, bottles, tubes, etc.)	Minimum labelled Shelf Life (Months)
1	2	3	4	5	6
1	9	Lignocaine Ointment 5%	10 gm Tube	180000	24
2	11	Lignocaine and Dextrose Injection IP Each ml contains Lignocaine 50 mg and Dextrose (monohydrate) 75 mg	2 ml Amp 25 ampoules	6000	24
3	56	Phenobarbitone Tablets IP 30 mg	10x10 Tab strip	1300000	36
4	60	Sodium Valproate Injection 100 mg/ml	5 ml Vial	90000	36
5	61	Sodium Valproate Tablets IP 200 mg (Enteric Coated)	10x10 Tab strip	5300000	36
6	63	Acyclovir Tablets IP 200 mg	10x10 Tab Blister	725000	36
7	80A	Azithromycin Tablets IP 500 mg	10x3x3 Tab strip/blister	10000000	24
8	82	Benzathine Benzylpenicillin Inj IP 6 lac units	Vial	30000	24
9	85	Cefixime Tablets IP 200 mg	10x10 Tab strip	40000000	24
10	99	Chloroquine Phosphate Tab. IP 250mg (=155 mg of Chloroquine base ) (Film Coated)	10x10 Tabs strip/ blister	33200000	36
11	122	Metronidazole Tablets IP 200 mg (Film Coated)	10x10 Tab Blister	15200000	48
12	133	Azathioprine Tablets IP 50 mg	10x10 Tablets strip	10000	36
13	137	Cisplatin Injection IP 50 mg/ 50 ml	50 ml vial	45000	24
14	138	Cyclophosphamide Injection IP 200 mg	10 ml glass vial	60000	24
15	146	Etoposide Injection IP 100 mg/ 5 ml	5 ml glass vial	19000	36
16	155	Paclitaxel Injection IP 260 mg	43.4 ml vial	47000	24

17	161	Levodopa and Carbidopa Tabs IP 250 mg + 25 mg	10x10 Tab Strip	341000	24
18	163	Acenocoumarol Tablets IP 2 mg	10x10 Tab strip	120000	24
19	165	Deferasirox Tablets 100 mg	30 Tab	300000	24
20	185	Amlodipine Tablets IP 5 mg	10x10 Tab Blister	15000000	36
21	189	Digoxin Injection IP 0.25 mg/ml	2 ml Amp 25 Ampoule	23000	24
22	211	Verapamil Tablets IP 40 mg Film Coated	10x10 Tab strip	186000	30
23	212	Verapamil Injection IP 2.5 mg/ ml	2 ml Amp 25 ampoules	29000	24
24	213	Acyclovir Cream BP 5%	5 g Tube	100000	36
25	221	Povidone Iodine Ointment 5%	15 gm Tube	2000000	24
26	229	Barium sulphate suspension	500 ml	6500	24
27	234	Fluorescein Eye Drops IP 1%	5 ml vial with sterilized dropper, or squeeze vial	16000	24
28	239	Mantoux Fluid (Tuberculin PPD IP)	5 ml vial	19000	60
29	243	Cetrimide Tincture 0.5% w/v (Cetrimide 0.5 w/v, Average Absolute Alcohol content 65.5% v/v)	200 ml Bottle (Amber colour)	99000	24
30	254	Frusemide Tablets IP 40 mg	10x10 Tabs Strip	3300000	48
31	285	Dinoprostone cream 0.5 mg	Syringe	40000	24
32	299	Propylthiouracil Tablets IP 50 mg	10x10 Tab strip	48000	24
33	302	Human Anti D Immunoglobulin IP Inj. 50mcg	PFS/Vial	1000	24
34	307	Rabies Vaccine Human (Cell Culture ) IP (Intramuscular ) 2.5 IU/ dose	Single dose vial with diluent and syringe with needle	800000	24
35	316	Neostigmine Tablets IP 15 mg	10x10 Tab strip	17000	36
36	330	Tobramycin and Dexamethasone Ophthalmic Suspension USP 0.3%+0.1%	5 ml vial with sterilized dropper, or squeeze vial	500000	24
37	337	Misoprostol Tablets 200 mcg	10x10 Tab	894000	24
38	339	Alprazolam Tablets IP 0.25 mg	10x10 Tab Blister	9700000	36

39	340	Alprazolam Tablets IP 0.5 mg	10x10 Tab Blister	9600000	36
40	341	Amitriptyline Tablets IP 25 mg Film Coated	10x10 Tab strip	1617000	36
41	343	Chlorpromazine Tablets 100 mg (Sugar coated)	10x10 Tab strip	100000	24
42	347	Clomipramine Capsules IP 25 mg	10x10 Cap Strip	147000	24
43	348	Clonazepam Tablets IP 1 mg	10x10 Tab Strip / blister	4600000	36
44	352	Fluoxetine Capsules IP 20 mg	10x10 Cap strip/ blister	1000000	36
45	356	Imipramine Tablets IP 25 mg (Coated Tablets)	10x10 Tab Blister	1000000	36
46	357	Imipramine Tablets IP 75 mg (Coated)	10x10 Tab Blister	100000	36
47	358	Lithium Carbonate Tablets IP 300 mg	10x10 Tab Strip	400000	24
48	359	Lorazepam Injection 2 mg/ ml	2 ml Amp 25 ampoules	60000	24
49	360	Olanzapine Tablets IP 5 mg	10x10 Tab strip	3700000	36
50	364	Trifluoperazine Tablets IP 5 mg Coated	10 x10 Tab Strip	50000	24
51	376	Theophylline Tablets 400 mg (Sustained Release/ Controlled Release)	10x10 Tab Blister	2038000	24
52	399	Concentrated Haemodialysis Fluid B.P Acetate concentrate in 10 Litre Cans. Each 1000ml After 1:34 dilutions should provide Sodium Chloride 135 to 140 meq/Litre sodium Acetate 35-38 meq/Litre Potassium Chloride 1.5-2 meq/Litre Magnesium chloride 1-1.5 meq/Litre calcium chloride 0-3 meq/Litre (depending on local condition) water purified to 1000 ml	10 Ltrs Plastic Can	5700	24
53	401	Peritoneal Dialysis Solution IP	1000 ml FFS/ BFS Pack	42000	24
54	405	Polygeline 3.5% Solution with electrolytes for IV Infusion	500 ml Plastic Bottle	2000	24
55	406	Factor- IX Concentrate (Purified) 600 IU (Human Coagulation Factor IX)	Vial with solvent	550	24
56	423	Hyaluronidase Injection IP Each vial contains Hyaluronidase IP 1500 IU	Vial	13000	36

57	433	Ranitidine Tablets IP 300 mg Film coated	10x10 Tab strip	10500000	24
58	444	Aspirin Delayed Release Tablets USP. Each enteric coated tablet contains Acetyl Salicylic Acid 75 mg	10 x 14 Tablets	8300000	24
59	465	Lisinopril Tablets IP 10 mg	10x10 Tab strip/ blister	300000	24
60	469	Prednisolone Tablets IP 10 mg	10 x 10 Tab strip	7000000	24
61	470	Prednisolone Tablets IP 20 mg	10x10 Tab strip/ blister	2500000	24
62	480	Dipttheria Antitoxin 10000 IU	Vial	5100	24
63	484	Timolol Eye Drops IP 0.5 % w/v	5 ml Vial with sterilized dropper, or, squeeze vial	25000	24
64	485	Homatropine Eye Drops IP 2 %	5 ml Vial with Sterilized dropper, or squeeze Vial	21000	36
65	486	Travoprost Ophthalmic Solution 0.004%	3 ml Vial with Sterilized dropper, or, squeeze vial	17000	24
66	491	Sevoflurane	250 ml Bottle	3000	24
67	492	Aceclofenac and Paracetamol Tablets Aceclofenac 100 mg and Paracetamol 325 mg	10x10 Tablet Blister	25000000	24
68	493	Diclofenac Gel: Diclofenac Diethylamine 1.16%, Methyl salicylate 10%, Linseed oil 3% and Menthol 5%	20 gm Tube	6500000	24
69	494	Etoricoxib Tablets 60 mg	10x10 Tablet Blister	155000	24
70	495	Etoricoxib Tablets 120 mg	10x10 Tablet Blister	200000	24
71	496	Mefenamic Acid Tablets BP 500 mg	10x10 Tablet	2700000	36
72	497	Anticold syrup: Each 5 ml contains Phenylephrine Hydrochloride 2.5 mg, Chlorpheniramine maleate 1 mg, and Paracetamol 125 mg	30 ml Bottle	9000000	24
73	498	Cetirizine, Phenylephrine & Paracetamol Tablets Cetirizine 5 mg, Phenylephrine 10 mg & Paracetamol 325 mg	10x10 Tablet	30000000	24
74	499	Cetirizine syrup IP 5 mg/ ml	30 ml Bottle	3000000	24



75	500	Acetylcystine Solution USP (Injection ) 200 mg/ ml	2 ml Ampoule (5x2 ml ampoules)	5300	24
76	501	Activated Charcoal Tablet 250 mg	10x10 Tablet	310000	24
77	502	Acyclovir Intravenous Infusion IP 250 mg	Vial	9100	24
78	503	Acyclovir Intravenous Infusion IP 500 mg	Vial	5000	24
79	504	Amikacin Injection IP 250 mg	Vial	1000000	24
80	505	Amoxicillin and Potassium Clavulante Injection IP 600 mg	Vial (10 ml)	330000	24
81	506	Amoxicillin and Potassium Clavulante Injection IP 1.2 g	Vial (20 ml)	600000	24
82	507	Amoxicillin and Potassium Clavulante Oral Suspension IP 200 mg + 28.5 mg per 5 ml	30 ml Bottle	900000	24
83	508	Artesunate Injection 60 mg	Vial	455000	24
84	509	Aztreonam Injection USP 500 mg	Vial	60000	24
85	510	Cefepime Injection IP 500 mg	Vial	25000	24
86	511	Cefixime Oral Suspension IP 25 mg/ ml (Paediatric Drops)	10 ml Bottle with a seperate dropper	300000	24
87	512	Cefuroxime Axetil Tablets IP 250 mg	10x10 Tablet Strip	2000000	24
88	513	Clindamycin Capsules IP 150 mg	10x10 Capsule strip/ blister	340000	48
89	514	Clindamycin Capsules IP 300 mg	10x10 Capsule strip/ blister	522000	48
90	515	Levofloxacin Tablets IP 250 mg	10x10 Tablet Blister	866000	36
91	516	Linezolid Tablets IP 600 mg	10x10 Tablet	225000	24
92	517	Linezolid Injection 200 mg/ 100 ml	100 ml	70000	24
93	518	Mefloquine Tablets IP 250 mg	10x6 Tablet Blister	56000	36
94	519	Metronidazole & Norfloxacin suspension 100 + 100 mg per 5 ml	30 ml Bottle with measuring cap	2050000	24
95	520	Ofloxacin and Ornidazole Tablets (Ofloxacin 200 mg and Ornidazole 500 mg)	10x10 Tablet Blister	5000000	24
96	521	Ofloxacin Infusion IP 200mg/ 100 ml (in NaCl Inj)	100 ml Bottle	400000	36
97	522	Pyrimethamine and Sulphadoxine Tablets IP (Pyrimethamine 37.5 mg and Sulphadoxine 750 mg)	2 Tablet Strip/ Blister 50x2 Tab	18000	24

98	523	Vancomycin for Intravenous Infusion IP 500 mg	Vial	96000	24
99	524	Vancomycin for Intravenous Infusion IP 1 g	Vial	9000	24
100	525	Alpha Interferon Injection (Interferon Alpha-2 concentrated Solution IP) 3 million unit	Vial	1050	24
101	526	Carboplatin Injection 150 mg USP/ BP	15 ml Vial	1530	24
102	527	Carboplatin Injection 450 mg USP/ BP	45 ml Vial	10000	24
103	528	Cisplatin Injection IP 10 mg/ 10 ml	10 ml Vial	1500	24
104	529	Dacarbazine Injection 500 mg USP/ BP	Vial	700	24
105	530	Filgrastim Injection (Granulocyte Colony Stimulation Factor) 300 mcg	PFS/ Vial	2600	24
106	531	Gemcitabine for Injection USP 200 mg	Vial	9000	24
107	532	Gemcitabine for Injection USP 1 gm	Vial	5000	24
108	533	Ifosfamide Injection USP/ BP 1 gm	Vial	17000	24
109	534	Imatinib Tablets 400 mg	10x10 Tablet	22000	24
110	535	Mesna Injection 200 mg	2 ml Ampoule (3x2ml ampoules)	3300	48
111	536	Methotrexate Tablets IP 10 mg	10x10 Tablet Strip	57000	24
112	537	Mitomycine for Injection USP 10 mg	Vial	1200	24
113	538	Oxaliplatin Injection USP 50 mg	25 ml Vial	11000	24
114	539	Bromocriptine Tablets IP 1.25 mg	10x10 Tablet Strip	6700	24
115	540	Bromocriptine Tablets IP 2.5 mg	10x10 Tablet Strip	6700	24
116	541	Betahistine Tablets IP 8 mg	10x10 Tablet	85000	36
117	542	Betahistine Tablets IP 16 mg	10x10 Tablet	97000	36
118	543	Cinnarizine Tablets IP 25 mg	10x10 Tablet Blister	1154000	24
119	544	Cinnarizine Tablets IP 75 mg	10x10 Tablet Blister	732000	24
120	545	Tranexamic Acid Tablets BP 500 mg	10x6 Tablet Blister	1200000	36
121	546	Warfarin Sodium Tablets IP 5 mg	10x10 Tablet	200000	24
122	547	Adenosine Injection USP 6 mg/ 2 ml	2 ml Vial	3800	24
123	548	Atorvastatin Tablets IP 40 mg	10x10 Tablet	2700000	24
124	549	Clopidogrel and Aspirin Tablets Clopidogrel 75 mg and Aspirin 75 mg	10x10 Tablet Strip	3500000	24

125	550	Fenofibrate Capsules IP 200 mg	10x10 Capsule	350000	24
126	551	Isoprenaline Injection IP 2 mg/ml	1 ml Ampoule 5x1 ml ampoules	10000	24
127	552	Metoprolol Tablets IP 25 mg	10x10 Tablet	1400000	36
128	553	Metoprolol Succinate Extended Release Tablets USP 50 mg	10x10 Tablet	1700000	24
129	554	Noradrenaline Injection IP 2 mg/ ml	2 ml Amp/ Vial	100000	18
130	555	Prazosin Tablets (Extended Release ) 2.5 mg	10x14 Tablet strip / blister	200000	24
131	556	Telmisartan Tablets IP 40 mg	10x10 Tablet	2600000	36
132	557	Urokinase Injection 5 Lac Unit (Lyophilized)	Vial	4300	24
133	558	Betamethasone Dipropionate Cream IP 0.05%	15 gm	900000	24
134	559	Betamethasone Lotion IP 0.05%	50 ml	200000	24
135	560	Clindamycin Phosphate Gel USP 1%	20 gm Tube	320000	24
136	561	Clobetasol Propionate Cream USP/ BP 0.05%	20 gm Tube	330000	24
137	562	Coal tar 4.25% and Salicylic Acid 2% Solution	50 ml	49000	24
138	563	Dithranol Ointment IP 0.5%	20 gm Tube	2200	24
139	564	Glycerin IP	100 ml Bottle	228000	36
140	565	Ketoconazole Cream 2%	15 gm Tube	153000	24
141	566	Neomycin sulphate and Bacitracin ointment USP 5 mg + 500 IU/ gm	15 gm Tube	260000	18
142	567	Permethrin Lotion 1%	30 ml	88000	24
143	568	Permethrin Lotion 5%	30 ml	163000	24
144	569	Permethrin Cream 5%	30 gm Tube	187000	24
145	570	Tretinoin Cream USP 0.025%	20 gm Tube	111000	24
146	571	Povidone Iodine Ointment USP 5%	250 gm Pack	126000	24
147	572	Povidone Iodine Solution IP 10%	100 ml Bottle	100000	24
148	573	Silver Sulphadiazine Cream USP 1%	500 gm Jar	56000	24
149	574	Spirolactone Tablets IP 50 mg	10x10 Tablet	364000	24
150	575	Finasteride Tablets IP 5 mg	10x10 Tablet strip/ blister	38000	24
151	576	Tamsulosin HCl Tablets 0.4 mg	10x10 Tablet Strip	339000	24
152	577	Terazosin Tablets USP 1 mg	10x10 Tablet	21000	24
153	578	Terazosin Tablets USP 2 mg	10x10 Tablet	21000	24
154	579	Flavoxate Tablets USP/ BP 200 mg	10x10 Tablet	239000	24

155	580	Chlorhexidine Mouthwash BP 0.2% / Chlorhexidine Oral rinse USP 0.2%	50 ml bottle	200000	24
156	581	Dental Gel: Choline salicylate 8.7%, Benzalkonium Chloride 0.01%, Lignocaine HCl 2% (flavoured gel base)	10 gm Tube	165000	24
157	582	Tooth Gel: Sodium Monofluorophosphate 0.7% and Potassium Nitrate 5% (in flavoured base)	50 gm Tube	192000	24
158	583	Gum Paint containg Tannic acid 2%, Cetrimide 0.1%, Zinc Chloride 1%	15 ml	142000	24
159	584	Metronidazole 1% and Chlorhexidine gluconate 0.25% Gel	10 gm Tube	121000	24
160	585	Ciprofloxacin 0.3% and Dexamethasone 0.1% Ear Drops Ciprofloxacin and Dexamethasone Otic Suspension USP	5 ml vial with sterilized dropper, or squeeze vial	1690000	24
161	586	Clotrimazole 1% with Beclomethasone Dipropionate 0.025% Ear Drops	5 ml ear drops	174000	24
162	587	Clotrimazole 1% with lignocaine 1% Ear Drops	5 ml ear drops	720000	24
163	588	Neomycin, Polymixin B and Hydrocortisone Ear Drops (Neomycin sulphate 3400 IU, Polymixin B Sulphate 10000 IU, and Hydrocortisone 10 mg per ml) Neomycin and Polymixin B Sulfate and Hydrocortisone Otic Solution USP	5 ml ear drops	171000	24
164	589	Ceruminolytic Drops (Wax dissolving ear drops): Paradichlorobenzene 2%, Benzocaine 2.7%, Chlorbutol 5%, Turpentine oil 15%	10 ml Bottle / Vial with a seperate dropper	577000	24
165	590	Domeperidone Oral Drops 10 mg/ ml	10 ml Bottle with a seperate dropper	1000000	24
166	591	Drotaverine & Mefenamic Acid Tablets Drotaverine 80 mg and Mefenamic Acid 250 mg	10x10 Tablet	1900000	24
167	592	Lactic Acid Bacillus Tablets 60 million spores	10x10 Tablet	10000000	24
168	593	Lactulose solution USP/ BP 10 gm/ 15 ml	100 ml Bottle	600000	24
169	594	Liquid Paraffin IP	100 ml Bottle	264000	24

170	595	Ondansetron Orally Disintegrating Tablets IP 4 mg	10x10 Tablet Strip	2100000	24
171	596	Pantoprazole 40 mg and Domperidone 30 mg SR Capsules Pantoprazole as enteric coated pellets, and Domperidone as sustained release pellets	10x10 Capsule Strip	9900000	24
172	597	Ursodeoxycholic Acid Tablets BP 300 mg	10x10 Tablet Strip/ blister	500000	24
173	598	Allopurinol Tablets IP 100 mg	10x10 Tablet	226000	24
174	599	Hydroxychloroquine Sulphate Tablets USP/ BP 200 mg	10x10 Tablet	192000	24
175	600	Leflunomide Tablets USP 10 mg (Film coated)	10x10 Tablet	74000	24
176	601	Leflunomide Tablets USP 20 mg (Film coated)	10x10 Tablet	54000	24
177	602	Sulfasalazine Delayed Release Tablets USP/ Gastroresistant Sulfasalazine Tablets BP 500 mg	10x10 Tablet	80000	24
178	603	Gliclazide and Metformin Tablets Gliclazide 80 mg and Metformin Hydrochloride 500 mg	10x10 Tablet	775000	24
179	604	Glucagon for Injection USP 1 mg/ ml	1 ml Vial	510	24
180	605	Medroxyprogesterone acetate Tablets IP 10 mg	10x10 Tablet	115000	24
181	606	Testosterone Propionate Injection IP 25 mg/ 1 ml	1 ml Vial	7200	32
182	607	Thyroxine Tablets IP 50 mcg	10x10 Tablet	1066000	24
183	608	Octreotide Injection 50 mcg/ ml	1 ml Ampoule	11000	24
184	609	Chlorzoxazone Tablets USP 250 mg	10x10 Tablet	800000	24
185	610	Chlorzoxazone , Diclofenac Sodium & Paracetamol Tablets ( Chlorzoxazone 250 mg, Diclofenac Sodium 50 mg & Paracetamol 325 mg)	10x10 Tablet	5112000	24
186	611	Betaxolol Ophthalmic Solution USP / Betaxolol Eye Drops, Solution BP 0.25%	5 ml Squeeze Vial	2300	24
187	612	Betaxolol Ophthalmic Solution USP/ Betaxolol eye Drops, Solution BP 0.5%	5 ml Squeeze Vial	1200	24
188	613	Carboxymethylcellulose Sodium Lubricant Eye Drops 0.5%	10 ml Squeeze Vial	142000	24
189	614	Phenylephrine Hydrochloride Ophthalmic Solution USP/ Phenylephrine Eye Drops BP 5%	5 ml vial with sterilized dropper, or	48000	24

			squeeze vial		
190	615	Mifepristone Tablets 200 mg	Single Tablet	23300	24
191	616	Formoterol Fumerate and Budesonide Powder for Inhalation IP 6 mcg + 200 mcg	30 Capsule (rotacaps)	207000	24
192	617	Budesonide Powder for Inhalation BP 200 mcg	30 Capsule (rotacaps)	628000	24
193	618	Ipratropium Powder for Inhalation IP 40 mcg	30 Capsule (Rotacaps)	397000	24
194	619	Terbutaline Tablets IP 2.5 mg	10x10 Tablet	712000	24
195	620	Xylometazoline Nasal Drops IP 0.1 %	5 ml Vial/ Bottle with a seperate dropper	231000	24
196	621	Sodium Chloride Injection IP	100 ml bottle	500000	24
197	622	Calcium Carbonate & vitamin D3 Tablets (Elemental Calcium 500 mg, Vitamin D3- 250 IU) Calcium with Vitamin D Tablets USP/ Calcium and Colecalciferol Tablets BP	10x10 Tablet	32183000	24
198	623	Cholecalciferol granules 60, 000 IU/ gm	1 gm sachet (50 Sachets)	244000	24
199	624	Mecobalamin Injection 500 mcg/ ml	1 ml Ampoule	130000	24
200	625	Nicotinamide Tablets IP 50 mg	10x10 Tablet	87000	36
201	626	Pyridoxine Tablets IP 10 mg	10x10 Tablet Strip	425000	36
202	627	Pyridoxine Tablets IP 40 mg	10x10 Tablet Strip	138000	36
203	628	Riboflavin Tablets IP 5 mg	10x10 Tablet Strip	562000	36
204	629	Thiamine Tablets IP 100 mg	10x10 Tablet Strip	331000	24
205	630	Calcitriol Capsules IP 0.25 mcg	10x10 Capsule strip/ blister	959000	24
206	631	Alendronate Sodium Tablets USP/ BP 35 mg	4 Tablet (20x4 Tablet)	59000	24
207	632	Mannitol with Glycerin Injection 10% +10% w/v (For Intravenous Infusion)	100 ml Bottle	21000	24

208	633	Normal Human Intravenous Immunoglobulin 5 g/ 100 ml	100 ml vial	1200	24
209	634	Pregabalin Capsules IP 75 mg	10x10 Capsule	214000	24
210	635	Surfactant for intratreacheal instillation (natural bovine lung surfactant)	4 ml vial	2400	18 (at 2-8°C)

Note:-

The above quantity mentioned for this supply cum rate contract is indicative and may vary as per the actual requirement of hospitals.

The bidder should quote rate for the above mentioned packing unit only.

General Requirement:-

1. The manufacturer should ensure Stability of the formulations and its ingredients in the packing supplied.
2. The blister packing of tablets/Capsules should have Aluminium foil back.
3. Strip packing should be of Aluminium / Alu- Alu foils.
4. Aluminium foil strips refer to thickness not less than 40 microns.
5. The rigid PVC used in blister packing should be of not less than 250 microns.
6. Small tablets packed in blister should be packed to facilitate easy removal of a tablet without breaking/ crushing.
7. Generic Name of drug should be printed in clearly legible bold letters.
8. Containers of external use preparations 400 ml or more, should have an inner lid also.

**RAJASTHAN MEDICAL SERVICES CORPORATION**  
**GUIDELINES**  
**FOR BLACKLISTING/DEBARRING OF**  
**PRODUCT OR SUPPLIER/COMPANY**

(Ref: Clause No. 13, 16 & 19 of Bid Document)

**1. ON SUBMISSION OF FALSE, FORGED OR FABRICATED DOCUMENTS OR CONCEALING OF FACTS:**

The Bidder who submits false, forged or fabricated documents or conceals facts with intent to win over the Bid or procure purchase order; EMD of such Bidder firm will be forfeited and firm will be liable for blacklisting for a period of not Less than 2 years. The firm will also be liable for Legal action depending on the facts & circumstances of the case.

**2. ON ACCOUNT OF FAILURE TO ENTER INTO AGREEMENT OR WITHDRAWAL AFTER AGREEMENT OR REFUSAL / FAILURE TO SUPPLY:**

2.1 The successful Bidder fails to execute the agreement after being declared as L-1, L-2 or L-3 etc. to perform the obligations under the Bid conditions, EMD of such Bidder firm will be forfeited and firm will be liable for blacklisting for a period of not less than 2 years or the period specified in Bid document.

2.2 The successful Bidder after entering into an agreement withdraw or fail to honour commitments as per Bid conditions, EMD of such Bidder firm will be forfeited and firm will be liable for blacklisting for a period of not Less than 2 years.

**3. ON ACCOUNT OF NON-SUPPLY:**

3.1 The supplier shall start to supply according to Bid condition from the date of purchase order and shall complete the supplies within 45/60 days as mentioned in Purchase Order or as stated in Bid condition.

RMSC will be at liberty to accept or reject the supply made belatedly as per the terms and conditions of the Bid documents. In the event of acceptance of delayed supply the liquidated damages shall be imposed at the rate stipulated in conditions of the Bid document.

3.3 If the supplier fails to execute the purchase order and informs RMSC about its inability to execute the order and non-compliance of the purchase order due to act of vis-majeure, then the Managing Director, RMSC will issue appropriate order on merits of case.

3.4 If the supplier fails to execute atleast 50% of the quantity mentioned in single purchase order and such failure in supply continues for three purchase orders, then supplier firm will be liable for blacklisting for a period of not Less than 2 years. As a result such supplier will be ineligible to participate in any of the Bids for particular item(s) of drugs / medicines for a period of not less than 2 years or the period specified in Bid document.



#### **4 ON ACCOUNT OF QUALITY FAILURE OF DRUGS & MEDICINES:**

- 4.1. The drugs supplied by the suppliers to the District Drug Warehouses are quarantined and samples of each and every batch of drugs /medicines are drawn on random basis and forwarded to Quality Control Wing of RMSC at the headquarter. The samples are then sorted; common batches pooled, coded and are sent to the empanelled laboratories for quality control test as per the QC Policy of RMSC.
- 4.2. Samples of all sterile surgicals & sutures items falling in the categories of drugs will also be drawn as per above policy and all of them will be subjected essentially for sterility testing.
- 4.3. If such samples **pass** quality test in all respects, RMSC will instruct its Warehouses to issue items of drugs to various hospitals / institutions
- 4.4. If the sample fails in quality test and report is received certifying that sample is **not of standard quality**, the drugs of the batch will not qualified for issue and supplier shall be informed to take back stocks of such batch, which failed the quality test and other consequences would follow as per the conditions in the Bid documents.
- 4.5. If **two batches of a particular item** supplied under a Bid tenure by the supplier are declared as **Not of Standard Quality** by an empanelled lab or Govt. Lab in **test for assay** and such failures are further confirmed by another empanelled lab / Govt. Lab, then the particular item of the drug shall be liable for blacklisting for a period of not Less than 2 years.
- 4.6. If **three batches of a particular item** supplied under a Bid tenure by the supplier are declared as **Not of Standard Quality** during its entire shelf life by an empanelled lab or Govt. Lab in **test for assay and / or in any other parameter(s)** and if such failures are further confirmed by another empanelled lab or Govt. Lab during its entire shelf life, the particular item of the drug shall be liable for blacklisting for a period of not Less than 2 years.
- 4.7. In case **three products of a company/supplier are blacklisted** for supply made during a Bid duration the **Supplier / Company** shall be liable for blacklisting for a period of not Less than 2 years.
- 4.8. In case, any sample (even one batch) is declared as **Spurious or Adulterated** by an empanelled lab or Govt. Lab and if such failure is further confirmed by another empanelled lab / Govt. Lab during its entire shelf life, the **Supplier / Company** shall be liable for blacklisting for a period of not less than 3 years.
- 4.9. If any statutory sample of RMSC supply drug is drawn by Drugs Control Officer on suo-moto basis or on complaint and if it fails in quality parameters, the report is conclusive till it is challenged by supplier / company. If it is

challenged then the report of Director, C.D.L., Kolkatta shall be conclusive and action as contemplated in foregoing paragraphs will be initiated in the matter of blacklisting of product or company. However if failure is of such nature wherein Drugs Controller of State grants prosecution sanction under Drugs & Cosmetics Act, 1940, then even failure of such one batch shall be considered adequate for blacklisting the product for not less than 2 years and in case of involvement of three different products the **Supplier / Company** as a whole shall be liable for blacklisting for a period of not Less than 3years.

## **5 PROCEDURE IN THE EVENT OF QUALITY FAILURE WILL INVOLVE THE FOLLOWING STEPS:**

- 5.1 On receipt of adverse quality test report from empanelled lab or Govt. Lab of a quarantined stock, instructions will be issued immediately through e-mail to the concerned District Drug Warehouses to not to release such stock and entries be made by QC Cell at headquarter in e-aushadhi software for batch rejection i.e. not to be released for distribution to institutions / DDC's.
- 5.2 Warehouse Incharge will take appropriate measures immediately to segregate such stock and label all cartons as "NOSQ Drugs-Not for release" and shift it from quarantine area to Non-Release / Rejected Drugs Area (which is under lock & key) till its lifting by the supplier.
- 5.3 Immediately on receipt of NOSQ report, the second sample should be sent to another empanelled lab / Govt. Lab by the QC Cell.
- 5.4 The supplier shall be informed immediately about the test results and instructions be issued to lift the entire stock at supplier's expenses of such batch no. drug which is declared as "NOSQ" by the empanelled lab / Govt. Lab. However, in case of serious quality failure i.e. if drug is declared or adjudged spurious, adulterated or grossly substandard, one of drug warehouse incharge will be directed to contact the District Drugs Control officer for drawing statutory sample of such batch as per Act. The DDW Incharge has to keep adequate quantity of such drug for statutory sampling by Drugs Control officer.
- 5.5 In case of drug declared as **Not of Standard Quality** on subsequent sampling after the batch was released the procedure given in sub-para 5.2 will be followed in respect of stock available with the warehouse. In respect of stock already issued and drug warehouse in charge will take immediate steps to RETRIEVE the unused stock of such drugs from all such institutions and D.D.C.s by all possible mode and means and he/she will ensure that no such NOSQ drug is further distributed to the patients and ensure effective recall.
- 5.6 On receipt of test report from empanelled lab / Govt. Lab, show cause notice will be issued immediately to the concerned supplier calling for

explanation within 3 days from the date of receipt of notice in respect of quality failure of concerned batches of drug. The supplier will be required to submit the batch manufacturing record, batch analysis report, raw material purchase record & raw material test reports etc. Opportunity for personal hearing, if desired by supplier, may also be accorded.

- 5.7 On confirmation of the test result by the second laboratory, the case will be referred to the disciplinary committee of RMSC for further action.
- 5.8 In case when the second report is contradictory to the first report, the statutory sample will be sent to Govt. Lab, whose report will be final and if the sample has been tested by the Govt. Lab at any stage, its report will be conclusive & final unless challenged as per provisions of Drugs & Cosmetics Act, 1940.

## **6. EXAMINATIONS OF ISSUES BY DISCIPLINARY COMMITTEE OF RMSC**

- 6.1. Each & every case of submission of false documents, failure to execute agreement, non-supply or quality failure, etc. will be referred to disciplinary committee of RMSC for examination on a case to case basis for making appropriate technical recommendation to Managing Director for further appropriate action.
- 6.2. The recommendations of disciplinary committee will be placed before the Managing Director, RMSC who shall take appropriate action which may deem fit in the light of facts & circumstances of the case by way imposing penalty or debarring or Blacklisting of the particular product or supplier/ company.
- 6.3. If, the quality failure is of such nature that a particular product has been blacklisted according to the procedure stated above, the supplier will not be eligible for participating in any of the Bids for the particular item floated by RMSC for the specified period. For such purpose period of blacklisting will be counted from date of issue of order and it will deemed to be over on completion of the period and as such no fresh orders will normally be required for re-eligibility purpose. Similarly if the supplier /company is blacklisted the supplier will not be eligible for participating in any of the Bids for any of the items during blacklisted period.

## **7. POWER OF REVIEW:**

Subsequent to the action taken on the basis of available facts if some new facts & evidences such as reversal of test results findings by Appellate Laboratories etc. are brought to the notice of the corporation, the Managing Director of RMSC will have the right to review the earlier action. He may seek advice from the disciplinary committee in such matters.

## **8 RIGHT TO APPEAL:**

Any supplier / company against whom the above action is taken may prefer an appeal within 30 days of date of blacklisting order to the Principal Health Secretary, Medical & Health Department, Govt. of Rajasthan who shall decide the same.

## **9 Savings:**

The blacklisting of particular product or supplier / firm will be done without prejudice to other penalty which may be imposed as per the conditions of Bid documents and also to other actions which may be initiated under Drugs and Cosmetics Act 1940 or any other law of land. RMSC will display names of such blacklisted products and companies on its website and also circulate the same among all stakeholders viz. PSME, DM&HS, DC including respective State Drug Controllers where the supplier / company is located.

## **10 JURISDICTION:**

In the event of any dispute arising out of the orders and implementation thereof, such dispute shall be subject to the jurisdiction of the Courts of Jaipur City only or Hon'ble Rajasthan High Court, Bench at Jaipur.

## **EXPLANATIONS:**

(i) Increase in the cost of raw materials, power cut, Labour strike, insolvency, closure of the factory would not be considered as act of vis-majeure.

(ii) The meaning of 'Spurious drugs' or 'Adulterated Drugs' will be construed in strict sense under the provisions of Drugs & Cosmetics Act, 1940. For the purpose of blacklisting a drug will be considered 'Spurious' if empanelled lab / Govt. Lab so declare the product or it is found containing either no drug or very poor drug contents on testing or it is purported to be manufactured of whom it is not truly a product or which is likely to cause grievous hurt within the meaning of Sec. 320 Of IPC. Similarly for the purpose of blacklisting a drug will be considered 'Adulterated' if empanelled lab / Govt. Lab so declare the product or it is found containing any poisonous, deleterious, harmful or toxic substances or which is likely to cause grievous hurt.

(iii) Purchase Orders, if any, already issued before taking any blacklisting action or replacement orders given in past will not be affected in view of action taken as per above guidelines but all strict quality checks shall be observed for each supply of products.

(iv) The action proposed as above is not in conflict to any express conditions laid down in corresponding Bid and in case of any overlapping, the Bid condition will prevail.

**Memorandum of Appeal under the Rajasthan Transparency in Public  
Procurement Act, 2012**

Appeal No..... of.....

Before the..... (First/Second Appellate Authority)

1. Particulars of appellant:

(i) Name of the appellant:

(ii) Official Address, if any:

(iii) Residential address:

2. Name and address of the respondent (S):

(i)

(ii)

(iii)

3. Number and date of the order appealed against and name and designation of the officer/ authority who passed the order (enclose copy), or a statement of a decision, action or omission of the Procuring Entity in contravention to the provisions of the Act by which the appellant is aggrieved:

4. If the Appellant proposes to be represented by a representative, the name and postal address of the representative:

5. Number of affidavits and documents enclosed with the appeal:

6. Ground of appeal:

.....  
.....  
.....  
.....

..... (Supported by an affidavit)

7.

Prayer:

.....  
...  
.....  
...  
.....

Place .....

Date .....

Appellant's Signature

**UNDERTAKING FOR EMPANELMENT**

I Name.....S/o.....Age.....Prop./Partner/Director/Power of attorney holder of firm M/s.....situated at (Complete address of Mfg. unit).....bearing drug license on Form 25 & 28 bearing Number..... &.....respectively, issued on dated.....valid/Renewed up to.....do here by declare on oath as follows:-

1. That I have applied for empanelment for supply of Drugs & Medicines for the items I have quoted in the tender as enlisted in Annexure –VII
2. That I/We have carefully read all the conditions of Bid in Ref.no. F.0(42) /RMSCL /PROCUREMENT /DRUG /NIT-1 / 2013 / 281 dated 26.2.2013 for supply Cum rate contract and empanelment for supply of Drug and Medicines For Rajasthan Medical Services Corporation and accept all conditions of Bid, including amendments if any.
3. That I will be considered empanelled for the items which are declared technically responsive.
4. That I have deposited the required fees for empanelment.

Date

Name & Signature  
with Seal

**Rajasthan Medical Services Corporation, Gandhi Block,  
Swasthaya Bhawan, C-Scheme, Jaipur**

Phone No: 0141-2228065, 2228064

E\_mail : rmsc.drugprocurement@yahoo.com

**F.02 (42)/RMSCL/PROCUREMENT/DRUG/NIT-1/2013/354**

**Dated: 20.03.2013**

**Subject:-Amended technical specifications and other conditions of bid document for the tender of drugs NIT NO. F.02 (42)/RMSCL/PROCUREMENT /DRUG/NIT-1/2013/281 dated 26.02.2013 due for opening on 09.04.2013**

**Ref: - Pre-bid conference held on 11.03.2013**

S. No.	Existing condition / technical specification/Packing Unit/Quantity (clause no.)	Amended condition / technical specification/ Packing Unit/Quantity.
1.	<b>E-BID FOR THE SUPPLY CUM RATE CONTRACT AND EMPANELMENT FOR SUPPLY OF DRUGS AND MEDICINES</b>	<b>E-BID FOR THE ANNUAL RATE CONTRACT CUM SUPPLY AND EMPANELMENT FOR SUPPLY OF DRUGS AND MEDICINES</b>
2.	Clause 24 (i) At the time of award of contract, the quantity of goods, originally specified in the bidding documents may be increased or decrease. There will not be any minimum quantity guaranteed against bid quantity.	Clause 24 (i) At the time of award of contract, the quantity of Drugs, originally specified in the bidding documents may be increased or decreased. There will not be any minimum quantity guaranteed against bid quantity. The tender quantity is only indicative. Actual purchase can be more or less than the bid quantity based on actual consumption in the hospitals during Rate Contract period. The supplier shall submit the supply commitment quantity'' in Annexure XII which will be used for the cases where the actual purchase quantity tends to increase substantially from the bid quantity.
3.	Clause 24 (iii) However a bidder is bound to supply up to approximate quantity indicated in bid document, considering the total production capacity & capacity dedicated to RMSC	Clause 24 (iii) However a bidder is bound to supply up to quantity indicated in bid document, considering the total production capacity & capacity dedicated to RMSC. Moreover, the actual purchases beyond Bid quantity may be made keeping in view the supply commitment of bidder to corporation.
4.	Clause 17.2 On receipt of the prescribed invoice, and RMSC analytical laboratory report regarding quality, the payment would be made in 30 days. Clause 17.3 The in charge of district drug warehouse will be required to acknowledge the drugs received & ensure entry in e- Aushdhi software online.	Clause 17.2 On receipt of the prescribed consolidated invoice duly stamped and signed by authorized signatory and analytical laboratory report regarding quality, the payment would be made in 30 days. Clause 17.3 The in charge of district drug warehouse (DDW) will acknowledge the drugs received & ensure entry in e- Aushdhi software online. .

5.	Annexure-VIII and BOQ:- Code No. 56 Phenobarbitone Tablets IP 30 mg, 337 – Misoprostol Tablet 200mcg, 357 Imipramine Tablets IP 75 mg (Coated) and 364 Trifluoperazine Tablets IP 5 mg(Coated)	Annexure-VIII and BOQ:- Drugs with Code No. 56,337, 357 and 364deleted
6.	Annexure-VIII and BOQ:- Code No 547 Adenosine Injection USP 6 mg/ 2 ml, Packing 2 ml Vial	Annexure- VIII and BOQ:- Code No 547 Adenosine Injection USP 6 mg/ 2 ml, Packing 2 ml Vial / Ampoule
7.	Annexure-VIII and BOQ:- Code No. 593 Lactulose solution USP/ BP 10 gm/ 15 ml	Annexure- VIII and BOQ:- Code No. 593 Lactulose solution USP/ BP 10 gm/ 15 ml or 3.35 gm/ 5ml
8.	Clause 2 (b) and 5 (l), (m)	Clause 2 (b) and 5 (l),(m) Add to the existing clause:- Provisional / Audited (by CA) Turnover, P&L , Balance sheet of financial year 2012-13 may be accepted but the firm has to submit audited final accounts before execution of agreement. If the firm fails to produce audited final accounts, it will be liable for action as applicable in the case of non execution of agreement.
9.	Clause 9	Clause 9.5 new sub clause (k) added:- If the purchase order quantity is very less (which do not make even a normal small batch size; order quantity is less than 1 lac Tab/Cap, or less than 10,000 injections/ bottles/ tubes), the supply may be allowed in brand name to ensure uninterrupted sustained supply. However, the label should possess the required logogram, and the price should not appear on the label.
10.	Clause 2(c) Bidder should have at least 3 years Market Standing as a manufacturer / importer for the product.	Clause 2(c) Bidder should have at least 3 years Market Standing as a manufacturer for the quoted product. In the case of imported products, the product should have minimum 3 years standing in the market. The importer should have at least 3 years standing as manufacturer/ importer of drugs in general.
11.	Clause 5(i) Market Standing Certificate issued by the Licensing Authority/ competent authority as a Manufacturer for the product for last 3 years (Certificate should be enclosed with list of items) should be enclosed. Items quoted should be highlighted in the market standing certificate. In the case of direct importer, evidence for importing the item for last three years will be produced. These may be bill of lading, bill of entry for last three years, or certificate of analysis done at importing cargo point in India.	Clause 5(i) Market Standing Certificate issued by the Licensing Authority/ competent authority as a Manufacturer for the product for last 3 years (Certificate should be enclosed with list of items) should be enclosed. Items quoted should be highlighted in the market standing certificate. For imported items, the quoted item should have 3 years market standing, for which bills of entry, sale invoices, etc should be submitted to establish the claim. The importing firm should have 3 years standing as importer / manufacturer of medicines in general. The manufacturer may submit his licence or MSC to establish 3 years standing; The importer firm may submit Bills of entry, etc of same or other drugs to establish 3 years for importing the items and to establish the market standing of the firm. The bidder shall submit valid import licence for import of the quoted item.



12.	Clause 13(2) and 13(8)	Clause 13(2) and 13(8):- 45 days is substituted with 60 days; and 60 days is substituted by 75 days regarding supply period.																																				
13.	Annexure-VIII and BOQ:- Code No 499 Cetirizine syrup IP 5 mg/ml	Annexure-VIII and BOQ:- Code No 499 Cetirizine syrup IP 5 mg/ 5ml																																				
14.	Annexure-VIII Code no 505 and 506 Minimum Shelf Life (Months) 24	Annexure-VIII Code no 505 and 506 Minimum Shelf Life (Months) 18																																				
15.	Annexure-VIII Code no 122, 239, 254, 513, 514, 535 Minimum Shelf Life (Months) 48 or 60	Annexure-VIII Code no 122, 239, 254, 513, 514, 535 Minimum Shelf Life (Months) 36																																				
16.	Clause 2(b) Average Annual turnover (for drugs and medicines including Surgical and sutures Business) in the last three financial years (2009-10 and 2010-11, 2011-12) shall not be less than Rs. 20 Crores. For SSI units of Rajasthan, the average annual turnover in the last three financial years (2009-10, 2010-11 and 2011-12) should not be less than Rs. 2 Crores. For drug items falling in the category of “eye preparations” and for drug code no. 243, 564& 594 the average annual turnover of last three years should not be less than Rs. 2 Cr.	Clause 2(b) Average Annual turnover (for drugs and medicines including Surgical and sutures Business) in the last three financial years (2009-10, 2010-11, 2011-12, 2012-13 [as mentioned in Point 5 of corrigendum]) shall not be less than Rs. 20 Crores. For SSI units of Rajasthan, the average annual turnover in the last three financial years (2009-10, 2010-11 and 2011-12, 2012-13[as mentioned in Point 5 of corrigendum]) should not be less than Rs. 2 Crores. For drug items falling in the category of “eye preparations” and for drug code no. 221, 243, 564, 594, 571, and 572 the average annual turnover of last three years should not be less than Rs. 2 Cr.																																				
17.	Clause 19.9 Line-2 :- 13.10, Clause 15.7 and in Clause 16.3 the penalty will be imposed on supplier	Clause 19.9 Line-2 :- 13.10, Clause 15.10 and in Clause 16.3 the penalty will be imposed on supplier																																				
18.	Annexure-VIII and BOQ:-	<table><tr><th colspan="6">Annexure-VIII and BOQ:- Add the following</th></tr><tr><th>S. No.</th><th>Code No.</th><th>Name of item with specification</th><th>Packing Unit</th><th>Estimated Tender Qty.(No. of tabs, Caps, ampoules, bottles, tubes, etc.)</th><th>Minimum labelled Shelf Life in Months</th></tr><tr><td>211</td><td>102</td><td>Ciprofloxacin Tablets IP 250 mg Film Coated</td><td>10 x10 Tab Blister</td><td>261000000</td><td>36</td></tr><tr><td>212</td><td>103</td><td>Ciprofloxacin Tablets IP 500 mg film Coated</td><td>10 x 10 Tab Blister</td><td>438000000</td><td>36</td></tr><tr><td>213</td><td>305</td><td>Human Anti Rabies Immunoglobulin Injection 150 IU/ ml</td><td>2 ml Vial</td><td>100</td><td>24</td></tr><tr><td>214</td><td>442</td><td>Saline Nasal Solution (Drops) (Sodium chloride 0.65%)</td><td>10 ml bottle with dropper / Squeeze bottle</td><td>200000</td><td>36</td></tr></table>	Annexure-VIII and BOQ:- Add the following						S. No.	Code No.	Name of item with specification	Packing Unit	Estimated Tender Qty.(No. of tabs, Caps, ampoules, bottles, tubes, etc.)	Minimum labelled Shelf Life in Months	211	102	Ciprofloxacin Tablets IP 250 mg Film Coated	10 x10 Tab Blister	261000000	36	212	103	Ciprofloxacin Tablets IP 500 mg film Coated	10 x 10 Tab Blister	438000000	36	213	305	Human Anti Rabies Immunoglobulin Injection 150 IU/ ml	2 ml Vial	100	24	214	442	Saline Nasal Solution (Drops) (Sodium chloride 0.65%)	10 ml bottle with dropper / Squeeze bottle	200000	36
Annexure-VIII and BOQ:- Add the following																																						
S. No.	Code No.	Name of item with specification	Packing Unit	Estimated Tender Qty.(No. of tabs, Caps, ampoules, bottles, tubes, etc.)	Minimum labelled Shelf Life in Months																																	
211	102	Ciprofloxacin Tablets IP 250 mg Film Coated	10 x10 Tab Blister	261000000	36																																	
212	103	Ciprofloxacin Tablets IP 500 mg film Coated	10 x 10 Tab Blister	438000000	36																																	
213	305	Human Anti Rabies Immunoglobulin Injection 150 IU/ ml	2 ml Vial	100	24																																	
214	442	Saline Nasal Solution (Drops) (Sodium chloride 0.65%)	10 ml bottle with dropper / Squeeze bottle	200000	36																																	

19.	Clause 24(1)	<div>Clause 24(1) For supplier to submit the supply commitment quantity’’</div> <div>Annexure-XII – Commitment of quantity (New added)</div> <table><tr><th>S. N o.</th><th>Quote d Code No. &amp; Name of Drugs</th><th>Monthly Capacity in all shifts in nos.</th><th>Annual Producti on Capacit y</th><th>Monthly supply Commitm ent to RMSC in nos.</th><th>Annual Supply Commit ment to RMSC in nos.</th></tr><tr><td>1.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>3.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>4.</td><td></td><td></td><td></td><td></td><td></td></tr></table> <div>Signature of Authorized Signatory</div>	S. N o.	Quote d Code No. & Name of Drugs	Monthly Capacity in all shifts in nos.	Annual Producti on Capacit y	Monthly supply Commitm ent to RMSC in nos.	Annual Supply Commit ment to RMSC in nos.	1.						2.						3.						4.					
S. N o.	Quote d Code No. & Name of Drugs	Monthly Capacity in all shifts in nos.	Annual Producti on Capacit y	Monthly supply Commitm ent to RMSC in nos.	Annual Supply Commit ment to RMSC in nos.																											
1.																																
2.																																
3.																																
4.																																
20.	<div>Clause 2(e)-Bid should not be submitted for the product/products for which the concern/company has been blacklisted/banned/ debarred either by Bid inviting Authority or Govt. of Rajasthan or by any other State/Central Govt. and its Drugs procurement agencies.</div> <div>Clause 2(f)-The concern/company/firm which stands blacklisted/banned/ debarred either by Bid Inviting Authority or Govt. of Rajasthan or by any other State/Central Government or its Drugs procurement agencies on the date of bid submission shall not be eligible to participate in the Bid. If a company/firm and any product were blacklisted for a specified period, then the same will become eligible after the blacklisting period is over. In case the period of blacklisting/banning is not specified, the firm shall be eligible to participate after two years of the date of issue of order of banning/blacklisted/ debarred.</div>	<div>Clause 2(e)- Bid should not be submitted for the product/products for which the concern/company has been blacklisted/banned/debarred either by Bid inviting Authority or Govt. of Rajasthan on any ground.</div> <div>The Bid should not be submitted for those products also for which the concern/company has been blacklisted/banned/debarred by any other State/Central Govt. and its central Drugs procurement agencies on the ground of quality of the products supplied or on the ground of submission of fake or forged documents or false information / facts.</div> <div>Clause 2(f)- The concern/company/firm which stands blacklisted/banned/debarred on any ground either by Bid Inviting Authority or Govt. of Rajasthan on the date of bid submission, shall not be eligible to participate in the Bid. The concern/company/firm which stands blacklisted/banned/debarred on the ground of quality of the products supplied or on the ground of submission of fake or forged documents or false information / facts, by any other State /Central Government or its central Drugs procurement agencies shall also not be eligible to participate in the Bid.</div> <div>If a company/firm and any product were blacklisted for a specified period, then the same will become eligible after the blacklisting period is over. In case the period of blacklisting/banning is not specified, the firm shall be eligible to participate after two years of the date of issue of order of banning/blacklisting/debarring.</div>																														

21.	Annexure VII, Para 4:- That our Firm/Company does not stand blacklisted/debarred or banned by any State or Central Government or by its drug procurement agencies, on the date of bid submission for supply of drugs/medicines in India.	Annexure VII, Para 4:- That our Firm/Company does not stand blacklisted, debarred or banned on any ground either by Bid Inviting Authority or Govt. of Rajasthan on the date of bid submission. Our Firm/Company also does not stand blacklisted, debarred or banned on the ground of quality of the products supplied or on the ground of submission of fake or forged documents or false information / facts, by any State or Central Government or by its central drug procurement agencies, on the date of bid submission for supply of drugs/medicines in India.
22.	BOQ	BOQ :- The BOQ is replaced with new BOQ. Some drugs have been deleted from old BOQ and four drugs have been added.

**Rest terms and condition will remain the same.**

**Executive Director (Proc.)  
RMSC**

**Rajasthan Medical Services Corporation, Gandhi Block,  
Swasthaya Bhawan, C-Scheme, Jaipur**

Phone No: 0141-2228065, 2228064

E\_mail : rmsc.drugprocurement@yahoo.com

**F.02 (42)/RMSCL/PROCUREMENT/DRUG/NIT-1/2013/361**

**Dated: 22-03-2013**

**Subject:-Corrigendum (ii) to bid document for the tender of drugs NIT  
NO. F.02 (42)/ RMSCL/PROCUREMENT/DRUG/ NIT-1/ 2013/  
281 dated 26.02.2013 due for opening on 09.04.2013**

The following amendment is made in the Above Tender.

1. Annexure-VIII and BOQ: The bid quantity of code no. 102 -  
Ciprofloxacin Tablets IP 250 mg Film Coated should be read as 26100000
2. For code no. 492, 498 & 610, the Market Standing of products containing  
Paracetamol 500 mg shall be accepted. However, the firm shall submit the  
product permission of the product as per the tender specification.

**Executive Director (Proc.)  
RMSC**